US5652224A

US5652224A - Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism

Info

Publication number: US5652224A
Application number: US08/393,734
Authority: US
Inventors: James M. Wilson; Karen Kozarsky; Jerome Strauss, III
Original assignee: University of Pennsylvania Penn
Current assignee: University of Pennsylvania Penn
Priority date: 1995-02-24
Filing date: 1995-02-24
Publication date: 1997-07-29
Anticipated expiration: 2015-02-24
Also published as: EP0811074A1; US7306794B2; CA2213254A1; ATE199099T1; GR3035812T3; ES2155932T3; AU5303196A; DE69611753D1; US6887463B2; DE69611753T2; CA2213254C; EP0811074B1; US20050112103A1; MX9706485A; WO1996026286A1; JP3868489B2; PT811074E; JPH11500623A; US6174527B1; DK0811074T3

Abstract

The invention provides a recombinant viral vector comprising the DNA of, or corresponding to, at least a portion of the genome of an adenovirus, which portion is capable of infecting a hepatic cell; and a human VLDL receptor gene operatively linked to regulatory sequences directing its expression. The vector is capable of expressing the normal VLDL receptor gene product in hepatic cells in vivo or in vitro. This viral vector is useful in the treatment of metabolic disorders caused by the accumulation of LDL in plasma, such as familial hypercholesterolemia or familial combined hyperlipidemia.

Description

This invention was supported by the National Institute of Health Grant Nos. DK 42193-05 and HD 29946. The United States government has rights in this invention.

FIELD OF THE INVENTION

The present invention relates to the field of somatic gene therapy and the treatment of genetic disorders related to lipoprotein metabolism.

BACKGROUND OF THE INVENTION

The metabolism of lipids, particularly cholesterol, involves the interaction of a number of lipoproteins and apolipoproteins. Very low density lipoprotein (VLDL) and apolipoprotein E (apoE) are key precursor molecules in the production of low density lipoprotein (LDL) and in the overall metabolism of lipids, including cholesterol. LDL is the major cholesterol-transport lipoprotein in human plasma.

The VLDL/apoE receptors are expressed in heart, skeletal muscle, and adipose tissue [F. M. Wittmaack et al, Endocrinol., 136(1):340-348 (1995)] with lower levels of expression in the kidney, placenta, pancreas, and brain. This receptor has been suggested to play a role in the uptake of triglyceride-rich lipoprotein particles by specific organs. The cDNA encoding the putative human VLDL receptor was recently cloned [M. E. Gafvels et al, Som. Cell Mol. Genet., 19:557-569 (1993), incorporated by reference herein]. The receptor for LDL is located in coated pits on the surfaces of cells in the liver and other organs.

As depicted in FIG. 1A, in a normal healthy human, the molecules apolipoprotein B48 (Apo-B48), apolipoprotein C-II (Apo-C-II) and Apo E form a chylomicron particle in plasma passing through the intestines, which interacts with a chylomicron remnant receptor in the liver. After metabolism of the chylomicrons taken up by the remnant receptor, the liver produces the primary lipoprotein, VLDL, which contains Apo-E, Apo-C-II and apolipoprotein B100 (Apo B100). VLDL is metabolized into LDL, which binds to the LDL receptor in the liver via Apo B100. The LDL receptor in the liver facilitates the uptake of LDL by receptor-mediated endocytosis. LDL is degraded in lysosomes, and its cholesterol is released for metabolic use.

Defects in the metabolism of such lipoproteins and/or receptors result in several serious metabolic disorders. The human disease familial hyper-cholesterolemia (FH) is caused primarily by one or more mutations in the gene encoding the LDL receptor. FH is characterized clinically by (1) an elevated concentration of LDL; (2) deposition of LDL-derived cholesterol in tendons and skin (xanthomas) and in arteries (atheromas); and (3) inheritance as an autosomal dominant trait with a gene dosage effect. Individuals with FH develop premature coronary heart disease, usually in childhood. Heterozygotes number about 1 in 500 persons, placing FH among the most common inborn errors of metabolism. Heterozygotes have twofold elevations in plasma cholesterol (350 to 550 mg/dl) from birth and tend to develop tendon xanthomas and coronary atherosclerosis after age 20. Homozygotes number 1 in 1 million persons and are characterized by severe hypercholesterolemia (650 to 1000 mg/dl), cutaneous xanthomas which appear within the first 4 years of life, and coronary heart disease which begins in childhood and frequently causes death before age 20. [J. Goldstein et al, "Familial Hypercholesterolemia", Chapter 48, in The Metabolic Basis of Inherited Disease, 6th ed., C. R. Scrivers et al (eds), McGraw-Hill Information Services Co., NY, N.Y., (1989) pp. 1215-1250].

Another metabolic disorder is familial combined hyperlipidemia (FCH) which was first associated with hyperlipidemia in survivors of myocardial infarction and their relatives. FCH patients generally have one of three phenotypes: (1) elevated levels of VLDL, (2) elevated levels of LDL, or (3) increases in the levels of both lipoproteins in plasma. Unlike FH, FCH appears in only 10 to 20 percent of patients in childhood, usually in the form of hypertriglyceridemia. Homozygosity for the trait may result in severe hypertriglyceridemia. [J. Goldstein et al, "Disorders of the Biogenesis and Secretion of Lipoproteins", Chapter 44B in The Metabolic Basis of Inherited Disease, 6th ed., C. R. Scrivers et al (eds), McGraw-Hill Information Services Co., NY, N.Y., (1989) pp. 1155-1156]. This disorder is also associated with the appearance of glucose intolerance and obesity in a number of individuals.

The most striking abnormality of FCH is marked elevation of VLDL content of plasma. Increased production of VLDL leads to an expanded plasma pool of VLDL in some individuals, but in others with more efficient lipolysis, it results in increased levels of LDL. FCH is characterized by an excess production of LDL, rather than a genetic defect in the LDL receptor. The LDL receptors of cultured fibroblasts appear to be normal in FCH patients.

Clinical experience suggests that FCH is at least five times as prevalent as FH, occurring in about 1 percent of the North American population. The predilection toward coronary artery disease among patients with this disorder makes it the most prominent known metabolic cause of premature atherosclerosis [J. Goldstein et al, cited above].

When LDL receptors are deficient as in FH (see FIG. 1B), or excess LDL is produced due to excess VLDL as in FCH, the efficient removal of LDL from plasma by the liver declines, and the level of LDL rises in inverse proportion to the receptor number. The excess plasma LDL is deposited in connective tissues and in scavenger cells, resulting in the symptoms of either disorder.

Presently, treatment for FH and FCH is directed at lowering the plasma level of LDL by the administration of drugs, i.e., combined administration of a bile acid-binding resin and an inhibitor of 3-hydroxy-3-methylglutaryl CoA reductase for treatment of FH and niacin for treatment of FCH. However, FH homozygotes with two nonfunctional genes are resistant to drugs that work by stimulating LDL receptors. Similarly, such drugs are not particularly effective in FCH. In FH homozygotes, plasma LDL levels can be lowered only by physical or surgical means.

Administration of normal LDL receptor genes by an adenovirus vector has been contemplated for the treatment of FH. Adenovirus vectors are capable of providing extremely high levels of transgene delivery to virtually all cell types, regardless of the mitotic state. The efficacy of this system in delivering a therapeutic transgene in vivo that complements a genetic imbalance has been demonstrated in animal models of various disorders [K. F. Kozarsky et al, Somatic Cell Mol. Genet., 19:449-458 (1993) ("Kozarsky et al I"); K. F. Kozarsky et al, J. Biol. Chem., 269:13695-13702 (1994) ("Kozarsky et al II); Y. Watanabe, Atherosclerosis, 36:261-268 (1986); K. Tanzawa et al, FEBS Letters, 118(1):81-84 (1980); J. L. Golasten et al, New Engl. J. Med., 309(11983):288-296 (1983); S. Ishibashi et al, J. Clin. Invest., 92:883-893 (1993); and S. Ishibashi et al, J. Clin. Invest., 93:1885-1893 (1994)]. The use of adenovirus vectors in the transduction of genes into hepatocytes in vivo has previously been demonstrated in rodents and rabbits [see, e.g., Kozarsky II, cited above, and S. Ishibashi et al, J. Clin. Invest., 92:883-893 (1993)].

Recent research has shown that introduction of a recombinant adenovirus encoding the human LDL receptor ("LDLR") cDNA into the livers of LDL receptor-deficient Watanabe heritable hyperlipidemic (WHHL) rabbits, which mimic the condition of FH, via an adenovirus vector resulted in large, transient reductions in plasma cholesterol. The transient nature of the effect of recombinant adenoviruses in most situations is the development of cellular immune responses to the virus-infected cells and their elimination. Antigenic targets for immune mediated clearance are viral proteins expressed from the recombinant viral genome and/or the product of the transgene, which in this case, is the LDL receptor protein [Y. Yang et al, Proc. Natl. Acad. Sci., USA, 91:4407-4411 (May 1994); Y. Yang et al, Immun., 1:433-442 (August 1994)].

Additionally, repeated reinfusions of the LDLR gene-containing adenovirus did not produce similar, subsequent cholesterol reductions due to the development of neutralizing anti-adenovirus antibodies [Kozarsky et al I and Kozarsky et al II, cited above; see also Y. Yang et al, Immun., 1:433-442 (August 1994), all incorporated by reference herein].

There remains a need in the art for therapeutic compositions and gene therapy strategies which enable effective treatment and/or prevention of FH and FCH, as well as other defects in lipoprotein metabolism.

SUMMARY OF THE INVENTION

In one aspect, the invention provides a recombinant viral vector comprising the DNA of, or corresponding to, at least a portion of the genome of an adenovirus, which portion is capable of infecting a hepatic cell; and a human VLDL receptor ("VLDLR") gene operatively linked to regulatory sequences directing its expression, the vector capable of expressing the VLDLR gene product in the hepatic cell in vivo or in vitro.

In another aspect, the invention provides a mammalian cell infected with the viral vector described above.

In still a further aspect, the invention provides a method for delivering and stably integrating a VLDLR gene into the chromosome of a mammalian hepatocyte cell comprising introducing into said cell an effective amount of a recombinant viral vector described above.

Another aspect of this invention is a method for treating a patient having a metabolic disorder comprising administering to the patient by an appropriate route an effective amount of an above described vector containing a normal VLDLR gene, wherein said VLDLR gene is integrated into the chromosome of said patient's hepatocytes and said receptor is expressed stably in vivo at a location in the body where it is not normally expressed.

Other aspects and advantages of the present invention are described further in the following detailed description of the preferred embodiments thereof.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A is a schematic drawing of normal human and rabbit lipoprotein metabolism. The apolipoproteins are referred to as B48, B100, C-II, and E. LDL and VLDL are identified.

FIG. 1B is a schematic drawing of lipoprotein metabolism in FH patients and WHHL rabbits. The abbreviations are as described in FIG. 1A.

FIG. 1C is a schematic drawing of lipoprotein metabolism in rabbits infused with the recombinant VLDLR gene according to the invention.

FIG. 2 is a schematic drawing of plasmid pAd.CMVVLDLR, which contains adenovirus map units 0-1 (Ad 0-1), followed by a cytomegalovirus enhancer/promoter (CMV enh/prom), a human VLDLR gene, a polyadenylation signal (pA), adenovirus map units 9-16 (Ad 9-16) and plasmid sequences from plasmid pAT153 including an origin of replication and ampicillin resistance gene. Restriction endonuclease enzymes are represented by conventional designations in the plasmid construct.

FIG. 3 is a schematic map of recombinant adenovirus H5.010CMVVLDLR, in which 0 to 100 represent the map units of an adenovirus type 5 (Genbank Accession No. M73260), and the CMV/VLDLR/pA minicassette of pAd.CMVVLDLR inserted between adenovirus m.u.1 and 9, with the remaining Ad5 map unit 9-100 having a partial E3 gene deletion between about map unit 78.5 and about 84.3.

FIG. 4A is a graph plotting changes in plasma cholesterol levels in mg/dl for WHHL rabbits vs. days before and after receiving recombinant adenovirus H5.010CMVlacZ. The symbols represent individual animals. See Example 3.

FIG. 4B is a graph plotting changes in plasma cholesterol levels in mg/dl for WHHL rabbits vs. days before and after receiving recombinant adenovirus H5.010CMVVLDLR. The symbols represent the response of four individual animals. See Example 3.

FIG. 5 is a bar graph representing cholesterol levels (measured as % pre-infusion) in mice infused with recombinant adenovirus H5.010CMVlacZ (lacZ), recombinant adenovirus H5.010CMVVLDLR and recombinant adenovirus H5.010CBhLDLR. The dotted bars represent pre-infusion levels and the solid bars represent post-infusion levels. See Example 4.

FIG. 6 is a bar graph representing cholesterol levels, specifically the levels of the fractions of plasma lipoproteins (measured as mg/fraction) in mice infused with recombinant adenovirus H5.010CMVlacZ (lacZ), recombinant adenovirus H5.010CMVVLDLR and recombinant adenovirus H5.010CBhLDLR. The solid bars represent proteins or fragments falling within a density (d)>1.21; the thickly cross-hatched bars represent HDL; the closely cross-hatched bars represent LDL, the spaced apart slanted hatched bars represent intermediate density lipoprotein (IDL), and the clear bars represent VLDL levels. See Example 4.

FIG. 7A is a graph plotting changes in cholesterol levels (measured in mg/dl) vs. days pre- and post-infusion for mice infused with H5.010CMVlacZ. The symbols represent the responses of individual animals. See Example 5.

FIG. 7B is a graph plotting changes in cholesterol levels (measured in mg/dl) vs. days pre- and post-infusion for mice infused with H5.010CBhLDLR. The symbols are the same as for FIG. 7A. See Example 5.

FIG. 7C is a graph plotting changes in cholesterol levels (measured in mg/dl) vs. days pre and post-infusion for mice infused with H5.010CMVVLDLR. The symbols are the same as for FIG. 9A. See Example 5.

FIG. 8 is the DNA sequence [SEQ ID NO: 1] with encoded amino acid sequence [SEQ ID NO: 2] of the human VLDL receptor gene, as reported by Gafvels et al, cited above.

FIG. 9 is the DNA sequence of pAd.CMVVLDLR [SEQ ID NO: 3], in which Ad 0-1 spans nucleotides 12-364, CMV ehn/prom spans nucleotides 381-862; nucleotides 966-4107 encode VLDLR, pA spans nucleotides 4192-4390; Ad 9.2-16.1 span nucleotides 4417-6880 and nucleotides 6881-9592 are pAT153 sequences.

FIG. 10A is an X-gal histochemical stain of liver sections of LDL knock-out mice injected with phosphate buffered saline on day 0 and sacrificed on day 3. See, Example 6.

FIG. 10B is an X-gal histochemical stain of liver section is of LDL knock-out mice injected with H5.010CMVlacZ on day 0 and sacrificed on day 3.

FIG. 10C is an X-gal histochemical stain of liver sections of LDL knock-out mice injected with H5.010CMVlacZ on day 0 and sacrificed on day 21.

FIG. 10E is an X-gal histochemical stain of liver sections Of LDL knock-out mice injected with H5.010CMVVLDLR on day 0 and sacrificed on day 3.

FIG. 10F is an X-gal histochemical stain of liver sections of LDL knock-out mice injected with H5.010CBhLDLR on day 0 and sacrificed on day 3.

FIG. 10G is an X-gal histochemical stain of liver sections of LDL knock-out mice injected with H5.010CBhLDLR on day 0 and sacrificed on day 10.

FIG. 10H is an X-gal histochemical stain of liver sections of LDL knock-out mice injected with H5.010CBhLDLR on day 0 and sacrificed on day 21.

FIG. 10I is an X-gal histochemical stain of liver sections of LDL knock-out mice injected with H5.010CBhLDLR on day 0 and sacrificed on day 3.

FIG. 10J is an X-gal histochemical stain of liver sections of LDL knock-out mice injected with H5.010CMVVLDLR on day 0 and sacrificed on day 3.

FIG. 10K is an X-gal histochemical stain of liver sections of LDL knock-out mice injected with H5.010CMVVLDLR on day 0 and sacrificed on day 10.

FIG. 10L is an X-gal histochemical stain of liver sections of LDL knock-out mice injected with H5.010CMVVLDLR on day 0 and sacrificed on day 21.

FIG. 11A is a Western gel for the experiment conducted as described in Example 7A. + is the positive control rabbit antiserum to LDL receptor. - is the pre-immune rabbit serum. KO20 and KO27 are LDL receptor knockout mice infused with H5.010CBhLDLR. C57Bl/6 represents two-separate mice infused with H5.010CBhLDLR. "pre" indicates lysates examined prior to injection. The numbers indicate days after injection.

FIG. 11B is a Western gel for the experiment conducted as described in Example 7B. Two individual LDL receptor knockout mice are represented as -/-; two individual normal (C57Bl/6) mice as (+/+); 24 and 27 are days after injection; pre is pre-immune serum. The positive control (+) is rabbit antibody to the VLDL receptor. The arrow indicates the presence of anti-VLDLR antibodies.

FIG. 12A is an X-gal histochemical stain of lymph nodes of C57Bl/6 mice adenovirus-infected on day 0 as described in Example 8 (magnification x100) depicting the staining of lymph nodes from normal mice ("control") necrotized on day 3.

FIG. 12B is a stain from control mice immunized as in FIG. 12A, and necrotized on day 28.

FIG. 12C is a stain from control mice, immunized as in FIG. 12A, and necrotized on day 31 following reinfection with lacZ-containing adenovirus vector on day 28.

FIG. 12D is a stain on day 3 of lymph nodes from mice immunized as in FIG. 12A, and depleted on days -3, 0, and +3 of CD4⁺ cells with mAb ("CD4 mAb").

FIG. 12E is a stain on day 28 of CD4 mAb mice immunized as in FIG. 12A.

FIG. 12F is a stain on day 31 of CD4 mAb mice immunized as in FIG. 12A.

FIG. 12G is a stain of lymph nodes from mice immunized as in FIG. 12A, and treated with IL-12 on days 0 and +1 ("IL-12") and necrotized on day 3.

FIG. 12H is a stain on day 28 of IL-12 mice immunized as in FIG. 12A.

FIG. 12I is a stain on day 31 of IL-12 mice immunized as in FIG. 12A.

FIG. 12J is a stain of lymph nodes from mice immunized as in FIG. 12A and treated with IFN-γ on days 0 and +1 ("IFN-γ") and necrotized on day 3.

FIG. 12K is a stain on day 28 of IFN-γ mice immunized as in FIG. 12A.

FIG. 12L is a stain on day 31 of IFN-γ mice, immunized as in FIG. 12A.

FIG. 13A is a graph summarizing neutralizing antibody titer present in BAL samples of C57Bl/6 mice adenovirus-infected on day 0 and necrotized on day 28 as described in Example 8. Control represents normal mice ("control"); CD4 mAB represents CD4+ depleted mice; IL-12 represents IL-12 treated mice and IFN-γ represent IFN-γ treated mice as described for FIGS. 12A through 12L.

FIG. 13B is a graph summarizing the relative amounts (OD₄₀₅) of IgG present in BAL samples. The symbols are as described in FIG. 13A.

FIG. 13C is a graph summarizing the relative amounts (OD₄₀₅) of IgA present in BAL samples. The symbols are as described in FIG. 13A.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides novel compositions and methods which enable the therapeutic treatment of metabolic disorders, such as FH and FCH, characterized by the accumulation of LDL in human plasma. This invention provides for the use of a viral vector to introduce and stably express a gene normally expressed in mammals, i.e., the gene encoding a normal receptor for very low density lipoprotein (VLDLR), in a location in the body where that gene is not naturally present, i.e., in the liver.

The method and compositions of the present invention overcome the problems previously identified in the gene therapy treatment of LDL receptor-deficient individuals. As described in detail below, by use of a viral vector capable of targeting cells of the liver, the VLDL receptor gene is introduced into, and stably expressed in, the cells of the liver. The present invention differs from direct gene replacement in that the VLDL receptor protein is expressed normally in LDL receptor deficient individuals, e.g., the macrophages. The gene therapy using this type of vector would result not in expression of a new gene product but in de novo expression in an organ which otherwise does not express the gene product. The patient does not mount an immune (specifically, a CTL-mediated) response against the VLDLR gene expressed in the liver (i.e., the vector-delivered VLDLR gene is not recognized as a foreign antigen). There is no induction of CTL-mediated elimination of the transfected cell. The opposite result occurs when an LDLR gene is administered to an LDLR-deficient individual with FH [see, e.g., Kozarsky I and II, cited above].

Due to this recognition of the VLDLR gene by the patient's immune system as a known gene, and to the tendency of hepatocytes to have a long life in circulation, the hepatocytes transfected with the vector of this invention, which express the VLDLR gene, tend to be stable and VLDLR expression is not transient. That is, insertion of the non-foreign VLDLR gene in hepatocytes permits the receptor gene to be expressed for the duration of the hepatocyte's life. This increases the duration of treatment of the lipoprotein metabolic disorder without the need for reinfusion of the vector, thus initially limiting possible formation of neutralizing anti-vector antibodies.

The vectors and methods of this invention can provide gene therapy useful to treat and/or supplement current treatments for lipoprotein metabolic disorders. The presence of the VLDL receptor gene in the transfected hepatocytes according to this invention permits the binding of VLDL, a precursor of LDL, from the plasma at the site of the liver, thereby decreasing the amount of VLDL in plasma. The decrease in VLDL in the plasma at this site consequently decreases the production of plasma LDL.

For example, in FH, this reduction in plasma LDL can compensate for the defective LDL receptors in the liver. In FCH, this reduced production of plasma LDL from VLDL prevents the normal LDL receptors in the liver from becoming overloaded by excess LDL, and reduces the excess VLDL which contributes to the disorder. Compare, for example, the schematic representations of the normal operation of lipid metabolism (FIG. 1A) to the abnormal metabolism caused by FH (FIG. 1B) and then to the method of this invention (FIG. 1C).

I. Recombinant Viral Particles as Gene Therapy Vectors

The compositions of this invention involve the construction of desirable gene therapy vectors, which are capable of delivering and stably integrating a functional, normal VLDL receptor gene, to hepatocytes. Such gene therapy vectors include a selected virus vector, desirably deleted in one or more viral genes, a minigene containing the VLDLR gene under the control of regulatory sequences, and optional helper viruses and/or packaging cell lines which supply to the viral vectors any necessary products of deleted viral genes.

The viral sequences used in the vectors, helper viruses, if needed, and recombinant viral particles, and other vector components and sequences employed in the construction of the vectors described herein are obtained from commercial or academic sources based on previously published and described sequences. These viral materials may also be obtained from an individual patient. The viral sequences and vector components may be generated by resort to the teachings and references contained herein, coupled with standard recombinant molecular cloning techniques known and practiced by those skilled in the art. Modifications of existing nucleic acid sequences forming the vectors, including sequence deletions, insertions, and other mutations taught by this specification may be generated using standard techniques.

The methods employed for the selection of viral sequences useful in a vector, the cloning and construction of VLDLR "minigene" and its insertion into a desired viral vector and the production of a recombinant infectious viral particle by use of helper viruses and the like are within the skill in the art given the teachings provided herein.

A. Construction of the "Minigene"

By "minigene" is meant the combination of the VLDLR gene and the other regulatory elements necessary to transcribe the gene and express the gene product in vivo. The human VLDL receptor sequence has been provided [see, Gafvels et al, cited above; SEQ ID NOS: 1 and 2]. Generally, the entire coding region of this receptor sequence is used in the minigene; the 5' and 3' sequences of SEQ ID NO: 1 are not essential to the minigene. VLDL receptor genes of other mammalian origin, e.g., rabbit, monkey, etc., may also be useful in this invention.

The VLDL receptor gene (VLDLR) is operatively linked to regulatory components in a manner which permits its transcription. Such components include conventional regulatory elements necessary to drive expression of the VLDLR transgene in a cell transfected with the viral vector. Thus the minigene also contains a selected promoter which is linked to the transgene and located, with other regulatory elements, within the selected viral sequences of the recombinant vector.

Selection of the promoter is a routine matter and is not a limitation of this invention. Useful promoters may be constitutive promoters or regulated (inducible) promoters, which will enable control of the amount of the transgene to be expressed. For example, a desirable promoter is that of the cytomegalovirus immediate early promoter/enhancer [see, e.g., Boshart et al, Cell, 41:521-530 (1985)]. Another desirable promoter includes the Rous sarcoma virus LTR promoter/enhancer. Still another promoter/enhancer sequence is the chicken cytoplasmic β-actin promoter [T. A. Kost et al, Nucl. Acids Res., 11(23):8287 (1983)]. Other suitable promoters may be selected by one of skill in the art.

The minigene may also desirably contain nucleic acid sequences heterologous to the viral vector sequences including sequences providing signals required for efficient polyadenylation of the transcript (poly-A or pA) and introns with functional splice donor and acceptor sites. A common poly-A sequence which is employed in the exemplary vectors of this invention is that derived from the papovavirus SV-40. The poly-A sequence generally is inserted in the minigene following the transgene sequences and before the viral vector sequences. A common intron sequence is also derived from SV-40, and is referred to as the SV-40 T intron sequence. A minigene of the present invention may also contain such an intron, desirably located between the promoter/enhancer sequence and the transgene. Selection of these and other common vector elements are conventional [see, e.g., Sambrook et al, "Molecular Cloning. A Laboratory Manual.", 2d edit., Cold Spring Harbor Laboratory, New York (1989) and references cited therein] and many such sequences are available from commercial and industrial sources as well as from Genbank.

As above stated, the minigene is located in the site of any selected deletion in the viral vector. See Example 1 below.

B. Construction of The Viral Plasmid Vector

Although a number of viral vectors have been suggested for gene therapy, the most desirable vector for this purpose is a recombinant adenoviral vector or adeno-associated vector. Adenovirus vectors as described below are preferred because they can be purified in large quantities and highly concentrated, and the virus can transduce genes into non-dividing cells. However, it is within the skill of the art for other adenovirus, or even retrovirus, vaccinia or other virus vectors to be similarly constructed.

Adenoviruses are eukaryotic DNA viruses that can be modified to efficiently deliver a therapeutic or reporter transgene to a variety of cell types. Human adenoviruses are comprised of a linear, approximately 36 kb double-stranded DNA genome, which is divided into 100 map units (m.u.), each of which is 360 bp in length. The DNA contains short inverted terminal repeats (ITR) at each end of the genome that are required for viral DNA replication. The gene products are organized into early (E1 through E4) and late (L1 through L5) regions, based on expression before or after the initiation of viral DNA synthesis [see, e.g., Horwitz, Virology, 2d edit., ed. B. N. Fields, Raven Press, Ltd. , New York (1990)]. The general adenoviruses types 2 and 5 (Ad2 and Ad5, respectively), are not associated with human malignancies.

Suitable adenovirus vectors useful in gene therapy are well known [see, e.g., M. S. Horwitz et al, "Adenoviridae and Their Replication" Virology, second edition, pp. 1712, ed. B. N. Fields et al, Raven Press Ltd., New York (1990); M. Rosenfeld et al, Cell, 68:143-155 (1992); J. F. Engelhardt et al, Human Genet. Ther., 4:759-769 (1993); Y. Yang et al, Nature Genet. 7:362-269 (1994); J. Wilson, Nature, 365:691-692 (Oct. 1993); B. J. Carter, in "Handbook of Parvoviruses", ed. P. Tijsser, CRC Press, pp. 155-168 (1990).

Adenovirus vectors useful in this invention may include the DNA sequences of a number of adenovirus types. The adenovirus sequences useful in the vectors described herein may be obtained from any known adenovirus type, including the presently identified 41 human types [see, e.g., Horwitz, cited above]. The sequence of a strain of adenovirus type 5 may be readily obtained from Genbank Accession No. M73260. Similarly, adenoviruses known to infect other animals may also be employed in the vector constructs of this invention. The selection of the adenovirus type is not anticipated to limit the following invention. A variety of adenovirus strains are available from the American Type Culture Collection, Rockville, Md., or available by request from a variety of commercial and institutional sources.

Adenovirus vectors useful in this invention include recombinant, defective adenoviruses optionally bearing other mutations, e.g., temperature sensitive mutations, deletions and hybrid vectors formed by adenovirus/adeno-associated virus sequences. Suitable vectors are described in the published literature [see, for example, Kozarsky I and II, cited above, and references cited therein, U.S. Pat. No. 5,240,846 and the copending applications incorporated herein by reference below.

In the construction of useful adenovirus vectors for delivery of the VLDLR gene to the liver, adenovirus nucleic acid sequences employed in the vectors can range from a minimum sequence amount, which vector requires the use of a helper virus to produce a hybrid virus particle, to only selected deletions of adenovirus genes, which deleted gene products can be supplied in the viral vector production process by a selected packaging cell line.

1. Recombinant Minimal Adenovirus

Desirable adenovirus (Ad) vectors useful in the present invention are described in detail in co-pending, co-owned U.S. patent application Ser. No. 08/331,381, which is incorporated by reference herein for the purpose of describing these vectors.

Briefly summarized, the minimal Ad virus is a viral particle containing only the adenovirus cis-elements necessary for replication and virion encapsidation, but otherwise deleted of all adenovirus genes. That is, the vector contains only the cis-acting 5' and 3' inverted terminal repeat (ITR) sequences of an adenovirus (which function as origins of replication) and the native 5' packaging/enhancer domain, that contains sequences necessary for packaging linear Ad genomes and enhancer elements for the E1 promoter. This left terminal (5') sequence of the Ad5 genome spans bp 1 to about 360 of the conventional published Ad5 adenovirus genome, also referred to as map units 0-1 of the viral genome, and generally is from about 353 to about 360 nucleotides in length. This sequence includes the 5'ITR (bp 1 to about 103 of the adenovirus genome); and the packaging/enhancer domain (bp about 194 to about 358 of the adenovirus genome). The minimal 3' adenovirus sequences of the adenovirus vector may include the right terminal (3') ITR sequence of the adenoviral genome spanning about bp 35,353--end of the adenovirus genome, or map units ˜98.4-100. This sequence is generally about 580 nucleotide in length. Between such sequences a VLDLR minigene, as described above, is inserted.

Production of an infectious particle from the this minimal Ad viral vector involves the assistance of a helper virus, as discussed below. A second type of minimal vector also disclosed in the above-incorporated reference places the 5' Ad terminal sequence in a head-to-tail arrangement relative to the 3' terminal sequence. The minimal Ad vector co-infected with a helper virus and/or a packaging cell line, provides all of the viral gene products necessary to produce an infective recombinant viral particle containing the VLDLR minigene. Alternatively, this vector can contain additional adenovirus gene sequences, which then are not required to be supplied by a helper gene.

2. Other Defective Adenoviruses

Recombinant, replication-deficient adenoviruses useful for gene therapy of this invention may be characterized by containing more than the minimal adenovirus sequences defined above. These other Ad vectors can be characterized by deletions of various portions of gene regions of the virus, and infectious virus particles formed by the optional use of helper viruses and/or packaging cell lines. Suitable defective adenoviruses are described in more detail in Kozarsky and Wilson, Curr. Opin. Genet. Devel., 3:499-503 (1993); Kozarsky I and II, cited above, and references cited therein, all incorporated herein by reference.

As one example, suitable vectors may be formed by deleting all or a sufficient portion of the adenoviral early immediate early gene E1a (which spans mu 1.3 to 4.5) and delayed early gene E1b (which spans mu 4.6 to 11.2) so as to eliminate their normal biological functions. These replication-defective E1-deleted viruses are capable of replicating and producing infectious virus when grown on an adenovirus-transformed, complementation human embryonic kidney cell line containing functional adenovirus E1a and E1b genes which provide the corresponding gene products in trans, the 293 cell [ATCC CRL1573]. The resulting virus is capable of infecting many cell types and can express a transgene (i.e., VLDLR gene), but cannot replicate in most cells that do not carry the E1 region DNA unless the cell is infected at a very high multiplicity of infection. Extensive experience in animals indicates this vector is not particularly desirable for gene therapy because low levels of viral proteins are expressed which elicit destructive cellular immune responses.

As another example, all or a portion of the adenovirus delayed early gene E3 (which spans mu 76.6 to 86.2) may be eliminated from the adenovirus sequence which forms a part of the hybrid construct. The function of E3 is irrelevant to the function and production of the recombinant virus particle. For example, Ad vectors may be constructed with a therapeutic minigene inserted into the E1-deleted region of the known mutant Ad5 sub360 backbone [J. Logan et al, Proc. Natl. Acad. Sci. USA, 81:3655-3659 (1984)]; or the Ad5 mutant d17001 backbone [Dr. William Wold, Washington University, St. Louis]. Both mutant viruses also contain a deletion in the E3 region of the adenoviral genome; in sub360, at 78.5 to 84.3 mu, and in d17001, at 78.4 to 86 mu. The life cycle of both sub360 and d17001 display wild type characteristics.

Adenovirus vectors may also be constructed having a deletion of the E1 gene, at least a portion of the E3 region, and an additional deletion within adenovirus genes other than E1 and E3 to accommodate the VLDLR minigene and/or other mutations which result in reduced expression of adenoviral protein and/or reduced viral replication. For example, all or a portion of the adenovirus delayed early gene E2a (which spans mu 67.9 to 61.5) may be eliminated from the adenovirus vector. It is also anticipated that portions of the other delayed early genes E2b (which spans mu 29 to 14.2) and E4 (which spans mu 96.8 to 91.3) may also be eliminated from the adenovirus vector.

Deletions may also be made in any of the late genes L1 through L5, which span mu 16.45 to 99 of the adenovirus genome. Similarly, deletions may be useful in the intermediate genes IX (which maps between mu 9.8 and 11.2) and IVa₂ (which maps between 16.1 to 11.1). Other deletions may occur in the other structural or non-structural adenovirus genes.

The above discussed deletions may occur individually, i.e., an adenovirus sequence for use in the present invention may contain deletions of E1 only. Alternatively, deletions of entire genes or portions effective to destroy their biological activity may occur in any combination. For example, in one exemplary vector, the adenovirus sequence may contain deletions of the E1 genes and the E3 gene, or of the E1, E2a and E3 genes, or of the E1 and E4 genes, or of E1, E2a and E4 genes, with or without deletion of E3, and so on.

Vectors may also contain additional mutations in genes necessary for viral replication. Adenovirus vectors may contain a mutation which produces temperature-sensitive (ts) virus. Among such mutations include the incorporation of the missense temperature-sensitive mutation in the (DBP)E2a region found in the Ad5 H5ts125 strain [P. Vander Vliet et al, J. Virol., 15:348-354 (1975)] at 62.5 mu. A single amino acid substitution (62.5 mu) at the carboxy end of the 72 kd protein produced from the E2a gene in this strain produces a protein product which is a single-stranded DNA binding protein and is involved in the replication of adenoviral genomic DNA. At permissive temperatures (approximately 32° C.) the ts strain is capable of full life cycle growth on HeLa cells, while at non-permissive temperatures (approximately 38° C.) no replication of adenoviral DNA is seen. In addition, at non-permissive temperatures, decreased immunoreactive 72 kd protein is seen in HeLa cells.

Exemplary vectors for use in this invention, for example, may be obtained by combining fragments from three independent DNA constructs including sub360 or d17001, H5ts125, and a cDNA plasmid with E1a sequences placed 5' to a therapeutic minigene. This type of vector is described by, for example, J. F. Engelhardt et al, Proc. Natl. Acad. Sci. USA, 91:6196-6200 (June 1994); Y. Yang et al, Nature Genet., 7: 362-369 (July, 1994) and references cited therein, all references incorporated herein by reference. Due to the mutations in the vector, there is reduced viral replication, reduction in expressed protein and an increase in the persistence of transgene expression. Other adenovirus vectors contain the H5ts125 mutation in addition to E3 deletions of sub360 and d17001. The minigene containing VLDLR as the transgene may be inserted into any deleted region of the selected Ad virus.

An exemplary Ad virus vector used to demonstrate this invention is the defective adenovirus vector H5.010CMVVLDLR, which contains adenovirus sequences Ad m.u. 0-1, followed by a VLDLR minigene, and the sequence Ad m.u.9 to 100 with small deletions in E3. See FIG. 3, described above. The recombinant adenovirus was fully deleted of E1a, E1b and partially deleted of E3. This recombinant virus vector is described in detail in Example 1.

3. Ad/AAV Hybrid Vectors

Another preferred vector is a hybrid Ad/AAV vector, which is the subject of co-owned, co-pending U.S. patent application Ser. No. 08/331,384, which is incorporated by reference herein.

At a minimum, the adenovirus nucleic acid sequences employed in the hybrid vector of this invention are the minimal adenovirus genomic sequences required for packaging adenoviral genomic DNA into a preformed capsid head, as described above. The entire adenovirus 5' sequence containing the 5'ITR and packaging/enhancer region can be employed as the 5' adenovirus sequence in the hybrid vector. The 3' adenovirus sequences of the vector include the right terminal (3') ITR sequence of the adenoviral genome discussed above. Some modifications to these sequences which do not adversely effect their biological function may be acceptable.

Also part of the hybrid vectors of this invention are sequences of an adeno-associated virus. The AAV sequences useful in the hybrid vector are the viral sequences from which the rep and cap polypeptide encoding sequences are deleted. More specifically, the AAV sequences employed are the cis- acting 5' and 3' inverted terminal repeat (ITR) sequences [See, e.g., B. J. Carter, cited above]. The AAV ITR sequences are about 143 bp in length. Substantially the entire sequences encoding the ITRs are used in the vectors, although some degree of minor modification of these sequences is expected to be permissible for this use. The ability to modify these ITR sequences is within the skill of the art. See, e.g., Sambrook et al, cited above.

In the hybrid vector construct, the AAV sequences are flanked by the adenovirus sequences discussed above. The 5' and 3' AAV ITR sequences themselves flank a VLDLR minigene sequence as described above. Thus, the sequence formed by the VLDLR minigene and flanking 5' and 3' AAV sequences may be inserted at any deletion site in the adenovirus sequences of the vector. For example, the AAV sequences are desirably inserted at the site of deleted E1a/E1b genes of the adenovirus, i.e., after map unit 1. Alternatively, the AAV sequences may be inserted at an E3 deletion, E2a deletion, and so on. If only the adenovirus 5' ITR/packaging sequences and 3' ITR sequences are used in the vector, the AAV sequences are inserted between them.

As described above for the minimum adenovirus sequences, those gene sequences not present in the adenovirus portion of the hybrid vector must be supplied by either a packaging cell line and/or a helper adenovirus to generate the recombinant hybrid viral particle. Uptake of this hybrid virus by the cell is caused by the infective ability contributed to the vector by the adenovirus and AAV sequences. Once the virus or virus conjugate is taken up by a cell, the AAV ITR flanked transgene must be rescued from the parental adenovirus backbone. Rescue of the transgene is dependent upon supplying the infected cell with an AAV rep gene.

The AAV rep gene can be supplied to the hybrid virus by several methods described in the above-incorporated application. One embodiment for providing rep proteins in trans is by transfecting into the target monolayer of cells previously infected with the hybrid vector, a liposome enveloped plasmid containing the genes encoding the AAV rep 78 kDa and 52 kDa proteins under the control of the AAV P5 promoter. More preferably for in vivo use, the AAV rep gene may also be delivered as part of the hybrid virus. One embodiment of this single particle concept is supplied by a polycation conjugate of hybrid virus. Infection of this modified virus conjugate is accomplished in the same manner and with regard to the same target cells as identified above. However, the polylysine conjugate of the hybrid virus onto which was directly complexed a plasmid that encoded the rep 78 and 52 proteins, combines all of the functional components into a single particle structure. Thus, the hybrid virus conjugate permits delivery of a single particle to the cell, which is considerably more desirable for therapeutic use. In another embodiment, the hybrid virus is modified by cloning the rep cDNA directly into the adenovirus genome portion of the hybrid vector.

These and additional aspects of this hybrid vector are provided by the above-incorporated by reference application.

C. Production of the Recombinant Viral Particle

1. Helper Viruses/Packaging Cell Lines

Depending upon the adenovirus gene content of the plasmid vectors employed to carry the VLDLR minigene, a packaging cell line or a helper adenovirus or both may be necessary to provide sufficient adenovirus gene sequences necessary to produce an infective recombinant viral particle containing the VLDLR minigene.

Useful helper viruses contain selected adenovirus gene sequences not present in the adenovirus vector construct or expressed by the cell line in which the vector is transfected. A preferred helper virus is desirably replication defective and contains a variety of adenovirus genes in addition to the modified sequences described above. In this setting, the helper virus is desirably used in combination with a packaging cell line that stably expresses adenovirus genes. Helper viruses may also be formed into poly-cation conjugates as described in Wu et al, J. Biol. Chem., 264:16985-16987 (1989); K. J. Fisher and J. M. Wilson, Biochem. J., 299:49 (Apr. 1, 1994), and in U.S. patent application Ser. No. 08/331,381, incorporated by reference herein.

Helper virus may optionally contain a second reporter minigene. A number of such reporter genes are known to the art. The presence of a reporter gene on the helper virus which is different from the transgene on the adenovirus vector allows both the Ad vector and the helper virus to be independently monitored. This second reporter is used to enable separation between the resulting recombinant virus and the helper virus upon purification. The construction of desirable helper cells is within the skill of the art.

As one example, if the cell line employed to produce the viral vector is not a packaging cell line, and the vector contains only the minimum adenovirus sequences identified above, the helper virus may be a wild type Ad vector supplying the necessary adenovirus early genes E1, E2a, E4 and all remaining late, intermediate, structural and non-structural genes of the adenovirus genome. However, if, in this situation, the packaging cell line is 293, which supplies the E1 proteins, the helper cell line need not contain the E1 gene.

In another embodiment, if the adenovirus vector construct is replication defective (no E1 gene and optionally no E3 gene) and the 293 cell line is employed, no helper virus is necessary for production of the hybrid virus. E3 may be eliminated from the helper virus because this gene product is not necessary for the formation of a functioning virus particle.

Preferably, to facilitate purification and reduce contamination of the viral vector particle with the helper virus, it is useful to modify the helper virus' native adenoviral gene sequences which direct efficient packaging, so as to substantially disable or "cripple" the packaging function of the helper virus or its ability to replicate.

A desirable "crippled" adenovirus is modified in its 5' ITR packaging/enhancer domain, which normally contains at least seven distinct yet functionally redundant sequences necessary for efficient packaging of replicated linear adenovirus genomes ("PAC" sequences). Within a stretch of nucleotide sequence from bp 194-358 of the Ad5 genome, five of these PAC sequences are localized: PAC I or its complement at bp 241-248 [SEQ ID NO: 4], PAC II or its complement at bp 262-269 [SEQ ID NO: 5], PAC III or its complement at bp 304-311 [SEQ ID NO: 6], PAC IV or its complement at bp 314-321 [SEQ ID NO: 7], and PAC V or its complement at bp 339-346 [SEQ ID NO: 8].

Mutations or deletions may be made to one or more of these PAC sequences in an adenovirus helper virus to generate desirable crippled helper viruses. Modifications of this domain may include 5' adenovirus sequences which contain less than all five of the native adenovirus PAC sequences, including deletions of contiguous or non-contiguous PAC sequences. An alternative modification may be the replacement of one or more of the native PAC sequences with one or more repeats of a consensus sequence containing the most frequently used nucleotides of the five native PAC sequences. Alternatively, this adenovirus region may be modified by deliberately inserted mutations which disrupt one or more of the native PAC sequences. One of skill in the art may further manipulate the PAC sequences to similarly achieve the effect of reducing the helper virus packaging efficiency to a desired level.

It should be noted that one of skill in the art may design other helper viruses or develop other packaging cell lines to complement the adenovirus deletions in the vector construct and enable production of the recombinant virus particle, given this information. Therefore, the use or description of any particular helper virus or packaging cell line is not limiting.

In the presence of other packaging cell lines which are capable of supplying adenoviral proteins in addition to the E1, the helper virus may accordingly be deleted of the genes encoding these adenoviral proteins. Such additionally deleted helper viruses also desirably contain crippling modifications as described above.

Poly-cation helper virus conjugates, which may be associated with a plasmid containing other adenoviral genes, which are not present in the helper virus may also be useful. The helper viruses described above may be further modified by resort to adenovirus-polylysine conjugate technology. See, e.g., Wu et al, cited above; and K. J. Fisher and J. M. Wilson, cited above.

Using this technology, a helper virus containing preferably the late adenoviral genes is modified by the addition of a poly-cation sequence distributed around the capsid of the helper virus. Preferably, the poly-cation is poly-lysine, which attaches around the negatively-charged vector to form an external positive charge. A plasmid is then designed to express those adenoviral genes not present in the helper virus, e.g., the E1, E2 and/or E4 genes. The plasmid associates to the helper virus-conjugate through the charges on the poly-lysine sequence. This conjugate permits additional adenovirus genes to be removed from the helper virus and be present on a plasmid which does not become incorporated into the virus during production of the recombinant viral vector. Thus, the impact of contamination is considerably lessened.

2. Assembly of Viral Particle and Infection of a Cell Line

Assembly of the selected DNA sequences of the adenovirus, the AAV and the reporter genes or therapeutic genes and other vector elements into the hybrid vector and the use of the hybrid vector to produce a hybrid viral particle utilize conventional techniques. Such techniques include conventional cloning techniques of cDNA such as those described in texts [Sambrook et al, cited above], use of overlapping oligonucleotide sequences of the adenovirus and AAV genomes, polymerase chain reaction, and any suitable method which provides the desired nucleotide sequence. Standard transfection and co-transfection techniques are employed, e.g., CaPO₄ transfection techniques using the complementation 293 cell line. Other conventional methods employed include homologous recombination of the viral genomes, plaquing of viruses in agar overlay, methods of measuring signal generation, and the like.

For example, following the construction and assembly of the desired minigene-containing plasmid vector, the vector is infected in vitro in the presence of an optional helper virus and/or a packaging cell line. Homologous recombination occurs between the helper and the vector, which permits the adenovirus-transgene sequences in the vector to be replicated and packaged into virion capsids, resulting in the recombinant vector viral particles. The current method for producing such virus particles is transfection-based. Briefly, helper virus is used to infect cells, such as the packaging cell line human HEK 293, which are then subsequently transfected with an adenovirus plasmid vector containing a VLDLR transgene by conventional methods. About 30 or more hours post-transfection, the cells are harvested, an extract prepared and the recombinant virus vector containing the VLDLR transgene is purified by buoyant density ultracentrifugation in a CsCl gradient.

The yield of transducing viral particles is largely dependent on the number of cells that are transfected with the plasmid, making it desirable to use a transfection protocol with high efficiency. One such method involves use of a poly-L-lysinylated helper adenovirus as described above. A plasmid containing the VLDLR minigene is then complexed directly to the positively charged helper virus capsid, resulting in the formation of a single transfection particle containing the plasmid vector and the helper functions of the helper virus.

II. Use of the Recombinant Virus Vectors in Gene Therapy

The resulting recombinant adenoviral vector containing the VLDLR minigene produced by cooperation of the adenovirus vector and helper virus or adenoviral vector and packaging cell line, as described above, thus provides an efficient gene transfer vehicle which can deliver the VLDLR gene to a patient in vivo or ex vivo and provide for integration of the gene into a liver cell.

The above-described recombinant vectors are administered to humans in a conventional manner for gene therapy and serve as an alternative or supplemental gene therapy for LDL receptor deficiencies or other lipoprotein metabolic disorders. A viral vector bearing the VLDLR gene may be administered to a patient, preferably suspended in a biologically compatible solution or pharmaceutically acceptable delivery vehicle. A suitable vehicle includes sterile saline. Other aqueous and non-aqueous isotonic sterile injection solutions and aqueous and non-aqueous sterile suspensions known to be pharmaceutically acceptable carriers and well known to those of skill in the art may be employed for this purpose.

The viral vectors are administered in sufficient amounts to transfect the liver cells and provide sufficient levels of transfer and expression of the VLDLR gene to provide a therapeutic benefit without undue adverse or with medically acceptable physiological effects which can be determined by those skilled in the medical arts. Conventional and pharmaceutically acceptable routes of administration include direct delivery to the liver, intranasal, intravenous, intramuscular, subcutaneous, intradermal, oral and other parental routes of administration. Routes of administration may be combined, if desired.

Dosages of the viral vector will depend primarily on factors such as the condition being treated, the age, weight and health of the patient, and may thus vary among patients. For example, a therapeutically effective human dosage of the viral vector is generally in the range of from about 20 to about 100 ml of saline solution containing concentrations of from about 1×10⁹ to 1×10¹¹ pfu/ml virus vector. A preferred human dosage is estimated to be about 50 ml saline solution at 2×10¹⁰ pfu/ml. The dosage will be adjusted to balance the therapeutic benefit against any side effects. The levels of expression of the VLDLR gene can be monitored to determine the frequency of dosage administration.

An optional method step involves the co-administration to the patient, either concurrently with, or before or after administration of the viral vector, of a suitable amount of a short acting immune modulator. The selected immune modulator is defined herein as an agent capable of inhibiting the formation of neutralizing antibodies directed against the recombinant vector of this invention or capable of inhibiting cytolytic T lymphocyte (CTL) elimination of the vector. The immune modulator may interfere with the interactions between the T helper subsets (T_H1 or T_H2) and B cells to inhibit neutralizing antibody formation. Alternatively, the immune modulator may inhibit the interaction between T_H1 cells and CTLs to reduce the occurrence of CTL elimination of the vector.

Immune modulators for use in inhibiting neutralizing antibody formation are selected based on the determination of the immunoglobulin subtype of any neutralizing antibody produced in response to the VLDLR-containing adenovirus vector. For example, if the neutralizing antibody is a T_H2 mediated antibody, such as IgA, the immune modulator desirably suppresses or prevents the interaction of T_H2 with B cells. Alternatively, if the neutralizing antibody is a T_H1 mediated antibody, such as IgG_2A, the immune modulator desirably suppresses or prevents the interaction of T_H1 with B cells.

The neutralizing antibody which develops in response to administration of a viral vector of this invention can be based on what vehicle is being used to deliver the vector and/or the location of delivery. For instance, administration of adenoviral vectors via the lungs generally induces production of IgA neutralizing antibody. Administration of adenoviral vectors via the blood generally induces IgG₁ neutralizing antibody. The determination of the neutralizing antibody is readily determined in trials of the selected viral vector in animal models.

Where the reduction of CTL elimination of the viral vectors is desired, the immune modulator is selected for its ability to suppress or block CD4+T_H1 cells to permit prolonged residence of the viral vector in vitro.

A desirable immune modulator which selectively inhibits the CD4+T cell subset T_H2 function at the time of primary administration of the viral vector includes interleukin-12, which enhances antigen specific activity of T_H1 cells at the expense of the T_H2 cell function [see, e.g., European Patent Application No. 441,900; P. Scott, Science,260:496 (1993); R. Manetti et al, J. Exp. Med., 177:1199 (1993); A. D'Andrea et al, J. Exp. Med., 176:1387 (1992)]. Another selected immune modulator which performs the same function is gamma interferon [S. C. Morris et al, J. Immunol., 152:1047 (1994); F. P. Heinzel et al, J. Exp. Med., 177:1505 (1993)]. Preferably, such immune modulators are in the form of human recombinant proteins. These proteins are currently commercially available or may be produced by methods extant in the art. It is also anticipated that active peptides, fragments, subunits or analogs of IL-12 or gamma interferon which share the T_H2 inhibitory function of these proteins, will also be useful in this method step when the neutralizing antibodies are T_H2 mediated.

A desirable immune modulator for use in this step of the method which selectively inhibits the CD4+ T cell subset T_H1 function at the time of primary administration of the viral vector includes interleukin-4, which enhances antigen specific activity of T_H2 cells at the expense of the T_H1 cell function [see, e.g., Yokota et al, Proc. Natl. Acad. Sci., USA, 83:5894-5898 (1986); U.S. Pat. No. 5,017,691].

Still other immune modulators which inhibit the T_H function may also be employed. Among such modulators are agents that specifically inhibit or deplete CD4+cells, for example, antibody to the CD4 protein. Among such agents include anti-T cell antibodies, such as anti-OKT 3+ [see, e.g., U.S. Pat. No. 4,658,019; European Patent Application No. 501,233, published Sep. 2, 1992, among others]. See, the examples which employ the commercially available antibody GK1.5 (ATCC Accession No. TIB207) to deplete CD4+ T_H1 cells. Depletion of CD4+ cells is shown to inhibit the CTL elimination of the viral vector.

Alternatively, any agent that interferes with the activation of B cells by T_H cells is useful. For example, it is necessary for the activation of B cells by T cells for certain interactions to occur [F. H. Durie et al, Immunol. Today, 15(9):406-410 (1994)], such as the binding of CD40 ligand on the T helper cell to the CD40 antigen on the B cell, and the binding of the CD28 and/or CTLA4 ligands on the T cell to the B7 antigen on the B cell. Without both interactions, the B cell cannot be activated to induce production of the neutralizing antibody.

Thus, agents which can block the interactions necessary for B cell activation by T helper cells, and thus neutralizing antibody formation can be used as immune modulators. An agent which blocks the CD40 ligand on the T_H cell interferes with the normal binding of CD40 ligand on the T helper cell with the CD40 antigen on the B cell. Thus, a soluble CD40 molecule or an antibody to CD40 ligand [available from Bristol-Myers Squibb Co; see, e.g., European patent application 555,880, published Aug. 18, 1993] can be a selected immune modulator.

Alternatively, an agent which blocks the CD28 and/or CTLA4 ligands present on T helper cells interferes with the normal binding of those ligands with the antigen B7 on the B cell. Thus, a soluble form of B7 or an antibody to CD28 or CTLA4, e.g., CTLA4-Ig [available from Bristol-Myers Squibb Co; see, e.g., European patent application 606,217, published Jul. 20, 1994] can be the selected immune modulator.

Although less desirable than the above-listed immune modulators, other immune modulators or agents that nonspecificly inhibit immune function, i.e., cyclosporin A or cyclophosphamide, may be useful in this method step.

A suitable amount or dosage of the immune modulator will depend primarily on the amount of the recombinant vector bearing the VLDLR gene which is initially administered to the patient and the type of immune modulator selected. Other secondary factors such as the condition being treated, the age, weight, general health, and immune status of the patient, may also be considered by a physician in determining the dosage of immune modulator to be delivered to the patient. Generally, for example, a therapeutically effective human dosage of a cytokine immune modulator, e.g., IL-12 or γ-IFN, is generally in the range of from about 0.5 μg to about 5 mg per about 1×10⁷ pfu/ml virus vector. Various dosages may be determined by one of skill in the art to balance the therapeutic benefit against any side effects.

It is presently preferred to administer the modulator just prior to the administration of the vector. The immune modulator may be administered separately from the recombinant vector, or, if desired, it may be administered in admixture with the recombinant vector. The immune modulator may be administered in a pharmaceutically acceptable carrier or diluent, such as saline. Alternatively, the immune modulator may be itself administered as DNA, either separately from the vector or admixed with the recombinant vector bearing the VLDLR gene. Methods exist in the art for the pharmaceutical preparation of the modulator as protein or as DNA [See, e.g., J. Cohen, Science, 259:1691-1692 (1993) regarding DNA vaccines]. Desirably the immune modulator is administered by the same route as the recombinant vector.

The optional administration of the selected immune modulator may be repeated during the treatment with the recombinant adenovirus vector carrying the human VLDLR gene, during the period of time that the VLDLR gene is expressed (as monitored by e.g., LDL levels), or with every booster of the recombinant vector.

Thus, the compositions and methods of this invention provide a desirable treatment for defects in LDL metabolism, by providing stable expression of the VLDLR gene in human hepatocytes, and the ability to re-administer the vector as desired without incurring an undesired immune response by the patient.

The following examples illustrate the construction and testing of the viral vectors and VLDL receptor gene inserts of the present invention and the use thereof in the treatment of metabolic disorders. An exemplary recombinant adenovirus encoding the human VLDL receptor was constructed as described in Example 1 below. These examples are illustrative only, and do not limit the scope of the present invention.

EXAMPLE 1 Construction and Purification of H5.010CMVVLDLR

The cDNA for the human very low density lipoprotein (VLDL) receptor [M. E. Gafvels et al, cited above; SEQ ID NO: 1] was inserted into the HindIII site of plasmid pRc/CMV (obtained from Invitrogen Corp.). The resulting plasmid, pRc/CMVVLDLR, was digested with the restriction enzymes SnaBI and NotI and the 4 kb fragment containing the cytomegalovirus (CMV) immediate-early promoter and VLDL receptor cDNA was isolated.

The plasmid pAd.CMVlacZ [Kozarsky II, cited above] was digested with SnaBI and NotI and the 5.6 kb backbone was isolated. The two fragments were ligated to generate pAd.CMVVLDLR (FIGS. 2 and 9; SEQ ID NO: 3). pAd.CMVVLDLR was linearized with NheI and co-transfected into 293 cells with sub360 DNA (derived from adenovirus type 5) which had been digested with XbaI and ClaI as previously described [K. F. Kozarsky I and II cited above].

The resulting recombinant adenovirus, designated H5.010CMVVLDLR contains the sequence from about nucleotide 12 to about 4390 of pAd.CMVVLDLR and Ad.5 map units 9-100 with a small deletion in the E3 gene (see GenBank Accession No. M73260) and discussion of FIG. 3. This recombinant adenovirus was isolated following two rounds of plaque purification. H5.010CMVVLDLR was grown on 293 cells and purified by two rounds of cesium chloride density centrifugation as previously described [K. F. Kozarsky I and II cited above]. Cesium chloride was removed by passing the virus over a BioRad DG10 column using phosphate-buffered saline.

For rabbit experiments, virus was used freshly purified; for mouse experiments virus was either used fresh, or after column purification glycerol was added to a final concentration of 10% (v/v), and virus was stored at -70° C. until use.

As described in the following examples, this recombinant adenovirus vector was introduced into the livers of WHHL rabbits and into the livers of LDL receptor knockout mice to determine the in vivo function of the VLDL receptor, and to determine its usefulness as an alternative or supplemental gene therapy for LDL receptor deficiency.

EXAMPLE 2 Other Recombinant Adenoviruses

H5.010CMVlacZ, encoding the lacZ gene under the control of the CMV enhancer/promoter, and H5.010CBhLDLR, encoding the human low density lipoprotein (LDL) receptor cDNA under the control of the CMV-enhanced chicken β-actin promoter, were prepared as previously described [K. F. Kozarsky I and II, cited above].

EXAMPLE 3 Effects of Hepatic Expression of the VLDL Receptor in the WHHL Rabbit

H5.010CMVVLDLR or H5.010CMVlacZ (encoding the β-galactosidase gene), obtained as described in Examples 1 and 2, was infused intravenously into WHHL rabbits [Camm Research] as follows. Rabbits were infused with 7.5×10¹² particles of either recombinant adenovirus through a marginal ear vein on day 0. In addition, two New Zealand White (NZW) rabbits [Hazleton, Inc.] were infused with each virus and sacrificed on day 5 post-infusion to document the extent of gene transfer in the liver.

Rabbits were maintained in a 12 hour light/dark cycle on a Purina laboratory chow, delivered each day at approximately 11:00 am. Venous samples were obtained through a marginal ear vein at approximately 10:00 am on the days indicated.

A. Plasma Analyses

Plasma samples were analyzed for total cholesterol using the Cholesterol HP kit and Preciset standards (Boehringer Mannheim).

Plasma cholesterol levels were evaluated in each of the WHHL rabbits before and after receiving recombinant adenovirus. FIG. 4A shows that rabbits infused with H5.010CMVlacZ had no significant changes in cholesterol levels. However, following infusion with H5.010CMVVLDLR, cholesterol levels dropped, with maximum decreases that ranged from 140 to 420 mg/dl (FIG. 4B). This demonstrated that expression of the VLDL receptor results in decreased cholesterol levels in LDL receptor-deficient rabbits.

B. Histochemical Analysis

Portions of liver were paraffin embedded, sectioned, and stained with hematoxylin and eosin. Some portions were fresh-frozen, sectioned, fixed in glutaraldehyde, stained with X-gal and lightly counterstained with hematoxylin. Some fresh-frozen sections were fixed in methanol, and then stained with either a polyclonal anti-β-galactosidase antibody (5 prime-3 prime), a polyclonal anti-human LDL receptor antibody, or with a polyclonal anti-VLDL receptor antibody, followed by a fluorescein isothiocyanate-conjugated anti-rabbit antibody (Jackson Immunoresearch) as previously described [K. F. Kozarsky I and II cited above]. Oil Red 0 staining was performed on fresh-frozen sections fixed for 1 minute in 37% formaldehyde, then rinsed and stained in Oil Red O (3 parts 0.5% Oil Red O in isopropyl alcohol/2 parts water) for 10 minutes. Slides were counterstained in hematoxylin and mounted in aqueous solution.

Immunofluorescence analysis of the infused rabbits showed that approximately 50% of hepatocytes from the rabbit infused with H5.010CMVlacZ expressed β-galactosidase, liver tissue from the rabbit infused with H5.010CMVVLDLR had a slightly higher percentage of hepatocytes expressing the VLDL receptor. In agreement with Northern blot analysis showing little or no VLDL receptor mRNA expression [M. E. Gafvels et al, cited above], liver from the lacZ-infused rabbit showed no reactivity with the anti-VLDL receptor antibody.

EXAMPLE 4 Effects of Short-Term Hepatic Expression of the VLDL Receptor in LDL Receptor Knockout Mice

C57Bl/6 mice and LDL receptor knockout mice (Jackson Labs) were infused intravenously with 0.5 or 1.0×10¹⁰ particles of recombinant adenovirus through the tail vein and cholesterol levels were monitored before and after infusion.

Specifically, three mice each were infused with either H5.010CMVlacZ, H5.010CMVVLDLR, or H5.010CBhLDLR (encoding the human LDL receptor cDNA). This last virus was included as a control to confirm published results [Kozarsky I and II cited above]. Plasma samples were obtained by retroorbital bleeds using heparinized capillary tubes. The LDL receptor knockout mice were maintained upon a high cholesterol diet composed of Purina mouse chow supplemented with 1.25% cholesterol, 7.5% cocoa butter, 7.5% casein, and 0.5% cholate (1.25% cholesterol diet) for at least 3 weeks immediately following weaning before experiments were initiated. Mice were sacrificed on day 5 post-infusion.

Liver tissues were analyzed by immunofluorescence for transgene expression by the techniques described in Example 3, and plasma cholesterol levels were measured as similarly described. For lipoprotein fractionations, plasma from triplicate LDL receptor knockout mice were pooled, subjected to density ultracentrifugation, fractions were collected, and the cholesterol content was determined by conventional means.

Immunofluorescence analysis revealed moderate levels of β-galactosidase expression in H5.010CMVlacZ-infused mice, and higher levels of either human LDL receptor and VLDL receptor expression in H5.010CBhLDLR- and in H5.010CMVVLDLR-infused mice, respectively.

Cholesterol levels decreased slightly in the control, H5.010CMVlacZ-infused mice (FIG. 5), probably due to non-transgene-related effects of infusion of recombinant adenovirus, which can result in hepatotoxicity in mice [Y. Yang et al, Proc. Natl. Acad. Sci., USA, 91:4407-4411 (May 1994)]. However, in contrast to the decrease observed in the control mice, cholesterol levels dropped significantly to 50% of pre-infusion values in the H5.010CBhLDLR-infused mice on day 5 post-infusion. Cholesterol levels in the H5.010CMVVLDLR-infused mice also decreased, to approximately 60% of pre-infusion levels. Further analysis of plasma lipoproteins showed that in the H5.010CBhLDLR-treated mice, LDL levels plummeted, with additional decreases in IDL and VLDL fractions (FIG. 6). The H5.010CMVVLDLR-infused mice showed a larger decrease in the VLDL fraction with less of a decrease in LDL.

Taken together, these data indicate that hepatic expression of VLDL receptor results in increased clearance of VLDL from the plasma, resulting in decreases in the amounts of lipoproteins for which VLDL is the precursor (i.e., IDL and LDL), and an overall drop in total plasma cholesterol.

EXAMPLE 5 Effects of Long-Term Hepatic Expression of the VLDL Receptor in LDL Receptor Knockout Mice

In order to achieve cholesterol levels closer to those observed in both FH patients and WHHL rabbits, LDL receptor knockout mice were maintained on a high cholesterol diet composed of Purina mouse chow supplemented with 0.2% cholesterol, 10% coconut oil, and 0.05% cholate (0.2% cholesterol diet). Cholesterol levels in these mice ranged from 930 to 1550 mg/dl, whereas the mice on the 1.25% cholesterol (Example 4) diet had levels of 1900 to 3100 mg/dl.

Three mice were each infused with 1×10¹¹ particles of a recombinant adenovirus selected from H5.010CBhLDLR, H5.010CMVVLDLR, or H5.010CMVlacZ. One mouse from each group was sacrificed on day 5 post-infusion to document the extent of gene transfer.

Immunofluorescence staining showed that most of the hepatocytes expressed the transgene product, either β-galactosidase, human LDL receptor, or VLDL receptor. Hematoxylin and eosin staining of sections of liver revealed essentially normal morphology in the H5.010CMVlacZ-infused mouse. However, for both the H5.010CBhLDLR- and H5.010CMVVLDLR-infused mice, hepatocytes appeared to have vacuoles within. When tissue was analyzed with Oil Red O staining, a stain for neutral lipids, liver from the receptor-infused animals clearly showed accumulation of large droplets of lipid when compared with the lacZ control. This suggested that short-term, high level expression of the LDL receptor or VLDL receptor in these LDL receptor-deficient mice resulted in intracellular accumulation of lipids.

To confirm the biologic activities of the transgene products, plasma cholesterol levels were followed before and after recombinant adenovirus administration. FIG. 7A shows that cholesterol levels in H5.010CMVlacZ-infused mice do not change significantly over time. Mice infused with H5.010CBhLDLR have a large but transient decrease in cholesterol (see, FIG. 7B). This is consistent with previous data indicating that recombinant adenovirus-mediated transgene expression is transient in mouse liver in large part or entirely due to the development of an immune response to the adenovirus-infected cells. Mice infused with H5.010CMVVLDLR showed large decreases in plasma cholesterol which paralleled those seen in the H5.010CBhLDLR-infused mice (FIG. 7C). Surprisingly, however, the decreases in cholesterol levels in the H5.010CMVVLDLR-infused mice (FIG. 7A) were sustained at least through 7 weeks following infusion (the current duration of the experiment). These data suggest that expression of the VLDL receptor in the liver is an effective therapy for hypercholesterolemia.

At the same time of infusion of the LDL receptor knockout mice, normal C57Bl/6 mice were infused with each of the recombinant adenoviruses. These mice were sacrificed on day 24 post-infusion, and immunofluorescence performed on liver tissues. This demonstrated that expression of β-galactosidase and of the human LDL receptor was nearly undetectable at this time point. In contrast, two mice infused with H5.010CMVVLDLR expressed the VLDL receptor at high levels. The percent of hepatocytes may have decreased slightly as compared to the day 5 mice. These data suggest that the sustained decrease in plasma cholesterol levels in the H5.010CMVVLDLR-infused mice was due to sustained expression of the VLDL receptor.

Western blots were performed using sera from these mice to determine the presence or absence of an immune response to the transgene products. Mice infused with H5.010CMVlacZ developed antibodies to β-galactosidase. In addition, mice infused with H5.010CBhLDLR synthesized antibodies to the human LDL receptor. However, antibodies to the VLDL receptor were undetectable in the mice infused with H5.010CMVVLDLR. This suggested that the VLDL receptor, although the human and not the mouse sequence was used, was not immunogenic in these mice. The amino acid sequences of the human and mouse LDL receptors are approximately 78% identical, while the human and mouse VLDL receptors are >94% identical. This increased sequence similarity is likely to account for the absence of antibody development to the human VLDL receptor despite high level expression in the mouse liver as a result of infusion of H5.010CMVVLDLR.

EXAMPLE 6 Stability of Expression of VLDL Receptor

This experiment illustrates relative transgene persistence in mice.

LDL receptor knockout mice were injected intravenously on day 0 with 1×10¹¹ particles of H5.010CMVlacZ, H5.010CBhLDLR, or H5.010CMVVLDLR. Mice were sacrificed on the indicated days after injection (3, 10 or 21), and fresh-frozen sections of liver were stained with one of X-gal (left column), anti-LDL receptor antibody (middle column) or anti-VLDL receptor antibody (right column) to detect expression of the lacZ gene, followed by a fluorescein-conjugated secondary antibody.

FIGS. 10A through 10L indicate the results, demonstrating that the expression of the VLDL receptor in mice persists longer than expression of either β-galactosidase (lacZ gene) or the human LDL receptor.

EXAMPLE 7 Western Blot to Detect Antibodies to the LDL Receptor and to the VLDL Receptor

A. This experiment confirmed earlier work that mice injected with H5.010CBhLDLR develop antibodies to the human LDL receptor.

Two LDL receptor knockout mice (KO20 and KO27) or two normal C57Bl/6 mice were injected via the tail vein with 1×10¹¹ particles of H5.010CBhLDLR at day 0 and serum samples were collected both before injection (pre), and on

days

10, 24,39,52 and 70 following injection for the knockout mice and on day 21 for the C57Bl/6 mice. The positive control (+) was rabbit antiserum to LDL receptor. The negative control (-) was pre-immune rabbit serum.

Lysates were prepared from 24-23 cells, a 3T3 cell line which produces retrovirus encoding the human LDL receptor, were subjected to SDS-polyacrylamide gel electrophoresis, and transferred to nitrocellulose filters. Filters were incubated with sera from the indicated mice, washed, and incubated with peroxidase-conjugated anti-mouse immunoglobulin followed by chemiluminescent substrate.

The results are depicted in the Western gel of FIG. 11A, which demonstrated that the mice injected with H5.010CBhLDLR develop antibodies to the human LDL receptor, as indicated by the band at the arrow in the indicated lanes.

B. This experiment confirmed that mice injected with H5.010CMVVLDLR generally do not develop antibodies to the VLDL receptor.

Two individual LDL receptor knockout mice (-/-) and two individual normal (C57Bl/6) mice (+/+) were injected via the tail vein with 1×10¹¹ particles of H5.010CMVVLDLR and serum samples were collected on the days 24 and 27 after injection or before injection (pre). The positive control (+) was rabbit antibody to the VLDL receptor.

Lysates were prepared from HeLa cells previously infected with H5.010CMVVLDLR, were subjected to SDS-polyacrylamide gel electrophoresis, and transferred to nitrocellulose filters. Filters were incubated with sera from the indicated mice, washed, and incubated with peroxidase-conjugated anti-mouse immunoglobulin followed by chemiluminescent substrate.

The Western gel as shown in FIG. 11B indicated that only a single mouse (an LDL knock-out mouse, 27 day sera) developed antibodies to the VLDL receptor. See, the fourth lane of FIG. 11B.

EXAMPLE 8 Enhancement of Adenovirus Mediated Gene Transfer upon Second Administration by IL-12 and IFN-γ in Mouse Lung

The recombinant adenoviruses H5.010CMVlacZ and H5.010CBALP (alkaline phosphatase gene expressed from the CMV enhanced β-actin promoter in the sub360 backbone) were used in this example. Each similar virus expresses a different reporter gene whose expression can be discriminated from that of the first reporter gene.

Female C57Bl/6 mice (6-8 week old) were infected with suspensions of H5.010CBALP (1×10⁹ pfu in 50 μl of PBS) via the trachea at day 0 and similarly with H5.010CMVlacZ at day 28. One group of such mice was used as a control. Another group of mice were acutely depleted of CD4⁺ cells by i.p. injection of antibody to CD4⁺ cells (GK1.5; ATCC No. TIB207, 1:10 dilution of ascites) at the time of the initial gene therapy (days--3, 0, and +3). A third group of mice were injected with IL-12 (1 μg intratracheal or 2 μg, i.p. injections) at the time of the first administration of virus (days 0 and +1). A fourth group of mice were injected with gamma interferon (1 μg intratracheal or 2 μg, i.p. injections) at the time of the first administration of virus (days 0 and +1).

When mice were subsequently euthanized and necropsied at

days

3, 28, or 31, lung tissues were prepared for cryosections, while bronchial alveolar lavage (BAL) and mediastinal lymph nodes (MLN) were harvested for immunological assays.

A. Cryosections

The lung tissues were evaluated for alkaline phosphatase expression by histochemical staining following the procedures of Y. Yang et al, cited above. The results are depicted in FIGS. 12A-12L.

Instillation of alkaline phosphatase virus (10⁹ pfu) into the airway of all groups of the C57Bl/6 mice resulted in high level transgene expression in the majority of conducting airways that diminishes to undetectable levels by day 28. Loss of transgene expression was shown to be due to CTL mediated elimination of the genetically modified hepatocytes [Y. Yang et al, cited above].

In the control mice, no recombinant gene expression was detected three days after the second administration of virus, i.e., day 31.

Administration of virus to the CD4+ depleted animals was associated with high level recombinant transgene expression that was stable for a month (FIGS. 12D-12F). Expression of the second virus was detectable on day 31.

Initial high level gene transfer diminished after about one month in the IL-12 treated mice; however, in contrast to the control, high level gene transfer to airway epithelial cells was achieved when virus was readministered to IL-12 treated animals at day 28, as seen in the day 31 results (FIG. 12G-12I).

The gamma-interferon treated animals were virtually indistinguishable from the animals treated with IL-12 in that efficient gene transfer was accomplished upon a second administration of virus (FIGS. 12J-12L).

B. Immunological Assays--MLN

Lymphocytes from MLN of the control group and IL-12 treated group of C57Bl/6 mice harvested 28 days after administration of H5.010CBALP were restimulated in vitro with UV-inactivated H5.010CMVlacZ at 10 particles/cell for 24 hours. Cell-free supernatants were assayed for the presence of IL-2 or IL-4 on HT-2 cells (an IL-2 or IL-4-dependent cell line) [Y. Yang et al, cited above]. Presence of IFN-γ in the same lymphocyte culture supernatant was measured on L929 cells as described [Y. Yang et al, cited above]. Stimulation index (S.I.) was calculated by dividing ³ H-thymidine cpm incorporated into HT-2 cells cultured in supernatants of lymphocytes restimulated with virus by those incorporated into HT-2 cells cultured in supernatants of lymphocytes incubated in antigen-free medium.

The results are shown in Table 1 below.

              TABLE 1
______________________________________
.sup.3 H-Thymidine Incorporation (cpm ± SD)
                          IFN-γ liter
Medium       H5.010CMVlacZ S.I.   (IU/ml).sup.d
______________________________________
C57Bl/6 175 ± 40
                 2084 ± 66  11.91
                                     80
anti-IL2          523 ± 81  2.98
(1:5000)
anti-IL4         1545 ± 33  8.83
(1:5000)
C57Bl/6 +
        247 ± 34
                 5203 ± 28  21.07
                                    160
IL12
anti-IL2          776 ± 50  3.14
(1:5000)
anti-IL4         4608 ± 52  18.66
(1:5000)
______________________________________

Stimulation of lymphocytes from regional lymph nodes with both recombinant adenoviruses led to secretion of cytokines specific for the activation of both T_H1 (i.e., IL-2 and IFN-γ) and T_H2 (i.e., IL-4) subsets of T helper cells (Table 1).

Analysis of lymphocytes from the IL-12 treated animals stimulated in vitro with virus revealed an increased secretion of IL-2 and IFN-γ and a relative decreased production of IL-4 as compared to animals that did not receive IL-12 (i.e., ratio of IL-2/IL-4 was increased from 3 to 6 when IL-12 was used; Table 1).

C. Immunological Assays--BAL

BAL samples obtained from animals 28 days after primary exposure to recombinant virus were evaluated for neutralizing antibodies to adenovirus and anti-adenovirus antibody isotypes as follows. The same four groups of C57Bl/6 mice, i.e., control, CD4⁺ depleted, IL-12 treated and IFN-γ treated, were infected with H5.010CBALP. Neutralizing antibody was measured in serially diluted BAL samples (100 μl) which were mixed with H5.010CBlacZ (1×10⁶ pfu in 20 μl), incubated for 1 hour at 37° C., and applied to 80% confluent Hela cells in 96 well plates (2×10⁴ cells per well). After 60 minutes of incubation at 37° C., 100 μl of DMEM containing 20% FBS was added to each well. Cells were fixed and stained for β-galactosidase expression the following day.

All cells were lacZ positive in the absence of anti-adenoviral antibodies.

Adenovirus-specific antibody isotype was determined in BAL by using enzyme-linked immunosorbent assay (ELISA). Briefly, 96-well plates were coated with 100 μl of PBS containing 5×10⁹ particles of H5.010CBlacZ for 18 hours at 4° C. The wells were washed 5 times with PBS. After blocking with 200 μl of 2% BSA in PBS, the plates were rinsed once with PBS and incubated with 1:10 diluted BAL samples for 90 minutes at 4° C. Thereafter, the wells were extensively washed and refilled with 100 μl of 1:1000 diluted alkaline phosphatase-conjugated anti-mouse IgG or IgA (Sigma). The plates were incubated, subsequently washed 5 times, and 100 μl of the substrate solution (p-nitrophenyl phosphate, PNPP) was added to each well. Substrate conversion was stopped by the addition of 50 μl of 0.1M EDTA. Plates were read at 405 nm.

The results are shown graphically in FIGS. 13A through 13C, which summarize neutralizing antibody titer, and the relative amounts (OD₄₀₅) of IgG and IgA present in BAL samples. The titer of neutralizing antibody for each sample was reported as the highest dilution with which less than 50% of cells stained blue.

As demonstrated in the first bar of FIGS. 13A through 13C, the cytokines identified in Table 1 above were associated in the control mice with the appearance of antibodies to adenovirus proteins in BAL of both the IgG and IgA isotypes that were capable of neutralizing the human Ad5 recombinant vector in an in vitro assay out to a 1:800 dilution.

As shown in the second bar of the graphs of FIGS. 13A through 13C, transient CD4⁺ cell depletion inhibited the formation of neutralizing antibody (FIG. 13A) and virus specific IgA antibody (FIG. 13C) by 80-fold, thereby allowing efficient gene transfer to occur following a second administration of virus (see FIG. 12F). FIG. 13B shows a slight inhibition of IgG as well.

More importantly, as shown in the third bar of the three graphs, IL-12 selectively blocked secretion of antigen specific IgA (FIG. 13C), without significantly impacting on formation of IgG (FIG. 13B). This was concurrent with a 32-fold reduction in neutralizing antibody (FIG. 13A).

The gamma-interferon treated animals (fourth bar of FIGS. 13A through 13B) were virtually indistinguishable from the animals treated with IL-12 in that virus specific IgA (FIG. 13C) and neutralizing antibody (FIG. 13A) were decreased as compared to the control animals not treated with cytokine, but not to the extent obtained with those treated with IL-12.

These studies demonstrate that inhibition of CD4⁺ function at the time of primary exposure to virus is sufficient to prevent the formation of blocking antibodies. The concordant reduction of neutralizing antibody with antiviral IgA suggests that immunoglobulin of the IgA subtype is primarily responsible for the blockade to gene transfer.

All references recited above are incorporated herein by reference. Numerous modifications and variations of the present invention are included in the above-identified specification and are expected to be obvious to one of skill in the art. Such modifications and alterations to the compositions and processes of the present invention, such as selections of different modifications of adenovirus vectors selected to carry the VLDLR gene, or selection or dosage of the vectors or immune modulators are believed to be within the scope of the claims appended hereto.

__________________________________________________________________________
SEQUENCE LISTING
(1) GENERAL INFORMATION:
(iii) NUMBER OF SEQUENCES: 8
(2) INFORMATION FOR SEQ ID NO:1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 3656 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: unknown
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 392..3010
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
CTCTGCGGGCCGCGGGTGCGGGTCGTCGCTACCGGCTCTCTCCGTTCTGTGCTCTCTTCT60
GCTCTCGGCTCCCCACCCCCTCTCCCTTCCCTCCTCTCCCCTTGCCTCCCCTCCTCTGCA120
GCGCCTGCATTATTTTCTGCCCGCAGCTCGGCTTGCACTGCTGCTGCAGCCCGGGGAGGT180
GGCTGGGTGGGTGGGGAGGAGACTGTGCAAGTTGTAGGGGAGGGGGTGCCCTCTTCTTCC240
CCGCTCCCTTCCCCAGCCAAGTGGTTCCCCTCCTTCTCCCCCTTTCCCCTCCCAGCCCCC300
ACCTTCTTCCTCTTTCGGAAGGGCTGGTAACTTGTCGTGCGGAGCGAACGGCGGCGGCGG360
CGGCGGCGGCGGCACCATCCAGGCGGGCACCATGGGCACGTCCGCGCTCTGG412
MetGlyThrSerAlaLeuTrp
15
GCCGTCTGGCTGCTGCTCGCGCTGTGCTGGGCGCCCCGGGAGAGCGGC460
AlaValTrpLeuLeuLeuAlaLeuCysTrpAlaProArgGluSerGly
101520
GCCACCGGAACCGGGAGAAAAGCCAAATGTGAACCCTCCCAATTCCAG508
AlaThrGlyThrGlyArgLysAlaLysCysGluProSerGlnPheGln
253035
TGCACAAATGGTCGCTGTATTACGCTGTTGTGGAAATGTGATGGGGAT556
CysThrAsnGlyArgCysIleThrLeuLeuTrpLysCysAspGlyAsp
40455055
GAAGACTGTGTTGACGGCAGTGATGAAAAGAACTGTGTAAAGAAGACG604
GluAspCysValAspGlySerAspGluLysAsnCysValLysLysThr
606570
TGTGCTGAATCTGACTTCGTGTGCAACAATGGCCAGTGTGTTCCCAGC652
CysAlaGluSerAspPheValCysAsnAsnGlyGlnCysValProSer
758085
CGATGGAAGTGTGATGGAGATCCTGACTGCGAAGATGGTTCAGATGAA700
ArgTrpLysCysAspGlyAspProAspCysGluAspGlySerAspGlu
9095100
AGCCCAGAACAGTGCCATATGAGAACATGCCGCATACATGAAATCAGC748
SerProGluGlnCysHisMetArgThrCysArgIleHisGluIleSer
105110115
TGTGGCGCCCATTCTACTCAGTGTATCCCAGTGTCCTGGAGATGTGAT796
CysGlyAlaHisSerThrGlnCysIleProValSerTrpArgCysAsp
120125130135
GGTGAAAATGATTGTGACAGTGGAGAAGATGAAGAAAACTGTGGCAAT844
GlyGluAsnAspCysAspSerGlyGluAspGluGluAsnCysGlyAsn
140145150
ATAACATGTAGTCCCGACGAGTTCACCTGCTCCAGTGGCCGCTGCATC892
IleThrCysSerProAspGluPheThrCysSerSerGlyArgCysIle
155160165
TCCAGGAACTTTGTATGCAATGGCCAGGATGACTGCAGCGATGGCAGT940
SerArgAsnPheValCysAsnGlyGlnAspAspCysSerAspGlySer
170175180
GATGAGCTGGACTGTGCCCCGCCAACCTGTGGCGCCCATGAGTTCCAG988
AspGluLeuAspCysAlaProProThrCysGlyAlaHisGluPheGln
185190195
TGCAGCACCTCCTCCTGCATCCCCATCAGCTGGGTATGCGACGATGAT1036
CysSerThrSerSerCysIleProIleSerTrpValCysAspAspAsp
200205210215
GCAGACTGCTCCGACCAATCTGATGAGTCCCTGGAGCAGTGTGGCCGT1084
AlaAspCysSerAspGlnSerAspGluSerLeuGluGlnCysGlyArg
220225230
CAGCCAGTCATACACACCAAGTGTCCAGCCAGCGAAATCCAGTGCGGC1132
GlnProValIleHisThrLysCysProAlaSerGluIleGlnCysGly
235240245
TCTGGCGAGTGCATCCATAAGAAGTGGCGATGTGATGGGGACCCTGAC1180
SerGlyGluCysIleHisLysLysTrpArgCysAspGlyAspProAsp
250255260
TGCAAGGATGGCAGTGATGAGGTCAACTGTCCCTCTCGAACTTGCCGA1228
CysLysAspGlySerAspGluValAsnCysProSerArgThrCysArg
265270275
CCTGACCAATTTGAATGTGAGGATGGCAGCTGCATCCATGGCAGCAGG1276
ProAspGlnPheGluCysGluAspGlySerCysIleHisGlySerArg
280285290295
CAGTGTAATGGTATCCGAGACTGTGTCGATGGTTCCGATGAAGTCAAC1324
GlnCysAsnGlyIleArgAspCysValAspGlySerAspGluValAsn
300305310
TGCAAAAATGTCAATCAGTGCTTGGGCCCTGGAAAATTCAAGTGCAGA1372
CysLysAsnValAsnGlnCysLeuGlyProGlyLysPheLysCysArg
315320325
AGTGGAGAATGCATAGATATCAGCAAAGTATGTAACCAGGAGCAGGAC1420
SerGlyGluCysIleAspIleSerLysValCysAsnGlnGluGlnAsp
330335340
TGCAGGGACTGGAGTGATGAGCCCCTGAAAGAGTGTCATATAAACGAA1468
CysArgAspTrpSerAspGluProLeuLysGluCysHisIleAsnGlu
345350355
TGCTTGGTAAATAATGGTGGATGTTCTCATATCTGCAAAGACCTAGTT1516
CysLeuValAsnAsnGlyGlyCysSerHisIleCysLysAspLeuVal
360365370375
ATAGGCTACGAGTGTGACTGTGCAGCTGGGTTTGAACTGATAGATAGG1564
IleGlyTyrGluCysAspCysAlaAlaGlyPheGluLeuIleAspArg
380385390
AAAACCTGTGGAGATATTGATGAATGCCAAAATCCAGGAATCTGCAGT1612
LysThrCysGlyAspIleAspGluCysGlnAsnProGlyIleCysSer
395400405
CAAATTTGTATCAACTTAAAAGGCGGTTACAAGTGTGAATGTAGTCGT1660
GlnIleCysIleAsnLeuLysGlyGlyTyrLysCysGluCysSerArg
410415420
GCCTATCAAATGGATCTTGCTACTGGCGTGTGCAAGGCAGTAGGCAAA1708
AlaTyrGlnMetAspLeuAlaThrGlyValCysLysAlaValGlyLys
425430435
GAGCCAAGTCTGATCTTCACTAATCGAAGAGACATCAGGAAGATTGGC1756
GluProSerLeuIlePheThrAsnArgArgAspIleArgLysIleGly
440445450455
TTAGAGAGGAAAGAATATATCCAACTAGTTGAACAGCTAAGAAACACT1804
LeuGluArgLysGluTyrIleGlnLeuValGluGlnLeuArgAsnThr
460465470
GTGGCTCTCGATGCTGACATTGCTGCCCAGAAACTATTCTGGGCCGAT1852
ValAlaLeuAspAlaAspIleAlaAlaGlnLysLeuPheTrpAlaAsp
475480485
CTAAGCCAAAAGGCTATCTTCAGTGCCTCAATTGATGACAAGGTTGGT1900
LeuSerGlnLysAlaIlePheSerAlaSerIleAspAspLysValGly
490495500
AGACATGTTAAAATGATCGACAATGTCTATAATCCTGCAGCCATTGCT1948
ArgHisValLysMetIleAspAsnValTyrAsnProAlaAlaIleAla
505510515
GTTGATTGGGTGTACAAGACCATCTACTGGACTGATGCGGCTTCTAAG1996
ValAspTrpValTyrLysThrIleTyrTrpThrAspAlaAlaSerLys
520525530535
ACTATTTCAGTAGCTACCCTAGATGGAACCAAGAGGAAGTTCCTGTTT2044
ThrIleSerValAlaThrLeuAspGlyThrLysArgLysPheLeuPhe
540545550
AACTCTGACTTGCGAGAGCCTGCCTCCATAGCTGTGGACCCACTGTCT2092
AsnSerAspLeuArgGluProAlaSerIleAlaValAspProLeuSer
555560565
GGCTTTGTTTACTGGTCAGACTGGGGTGAACCAGCTAAAATAGAAAAA2140
GlyPheValTyrTrpSerAspTrpGlyGluProAlaLysIleGluLys
570575580
GCAGGAATGAATGGATTCGATAGACGTCCACTGGTGACAGCGGATATC2188
AlaGlyMetAsnGlyPheAspArgArgProLeuValThrAlaAspIle
585590595
CAGTGGCCTAACGGAATTACACTTGACCTTATAAAAAGTCGCCTCTAT2236
GlnTrpProAsnGlyIleThrLeuAspLeuIleLysSerArgLeuTyr
600605610615
TGGCTTGATTCTAAGTTGCACATGTTATCCAGCGTGGACTTGAATGGC2284
TrpLeuAspSerLysLeuHisMetLeuSerSerValAspLeuAsnGly
620625630
CAAGATCGTAGGATAGTACTAAAGTCTCTGGAGTTCCTAGCTCATCCT2332
GlnAspArgArgIleValLeuLysSerLeuGluPheLeuAlaHisPro
635640645
CTTGCACTAACAATATTTGAGGATCGTGTCTACTGGATAGATGGGGAA2380
LeuAlaLeuThrIlePheGluAspArgValTyrTrpIleAspGlyGlu
650655660
AATGAAGCAGTCTATGGTGCCAATAAATTCACTGGATCAGAGCATGCC2428
AsnGluAlaValTyrGlyAlaAsnLysPheThrGlySerGluHisAla
665670675
ACTCTAGTCAACAACCTGAATGATGCCCAAGACATCATTGTCTATCAT2476
ThrLeuValAsnAsnLeuAsnAspAlaGlnAspIleIleValTyrHis
680685690695
GAACTTGTACAGCCATCAGGTAAAAATTGGTGTGAAGAAGACATGGAG2524
GluLeuValGlnProSerGlyLysAsnTrpCysGluGluAspMetGlu
700705710
AATGGAGGATGTGAATACCTATGCCTGCCAGCACCACAGATTAATGAT2572
AsnGlyGlyCysGluTyrLeuCysLeuProAlaProGlnIleAsnAsp
715720725
CACTCTCCAAAATATACCTGTTCCTGTCCCAGTGGGTACAATGTAGAG2620
HisSerProLysTyrThrCysSerCysProSerGlyTyrAsnValGlu
730735740
GAAAATGGCCGAGACTGTCAAAGTACTGCAACTACTGTGACTTACAGT2668
GluAsnGlyArgAspCysGlnSerThrAlaThrThrValThrTyrSer
745750755
GAGACAAAAGATACGAACACAACAGAAATTTCAGCAACTAGTGGACTA2716
GluThrLysAspThrAsnThrThrGluIleSerAlaThrSerGlyLeu
760765770775
GTTCCTGGAGGGATCAATGTGACCACAGCAGTATCAGAGGTCAGTGTT2764
ValProGlyGlyIleAsnValThrThrAlaValSerGluValSerVal
780785790
CCCCCAAAAGGGACTTCTGCCGCATGGGCCATTCTTCCTCTCTTGCTC2812
ProProLysGlyThrSerAlaAlaTrpAlaIleLeuProLeuLeuLeu
795800805
TTAGTGATGGCAGCAGTAGGTGGCTACTTGATGTGGCGGAATTGGCAA2860
LeuValMetAlaAlaValGlyGlyTyrLeuMetTrpArgAsnTrpGln
810815820
CACAAGAACATGAAAAGCATGAACTTTGACAATCCTGTGTACTTGAAA2908
HisLysAsnMetLysSerMetAsnPheAspAsnProValTyrLeuLys
825830835
ACCACTGAAGAGGACCTCTCCATAGACATTGGTAGACACAGTGCTTCT2956
ThrThrGluGluAspLeuSerIleAspIleGlyArgHisSerAlaSer
840845850855
GTTGGACACACGTACCCAGCAATATCAGTTGTAAGCACAGATGATGAT3004
ValGlyHisThrTyrProAlaIleSerValValSerThrAspAspAsp
860865870
CTAGCTTGACTTCTGTGACAAATGTTGACCTTTGAGGTCTAAACAAATAATACCCC3060
LeuAla
CGTCGGAATGGTAACCGAGCCAGCAGCTGAAGTCTCTTTTTCTTCCTCTCGGCTGGAAGA3120
ACATCAAGATACCTTTGCGTGGATCAAGCTTGCTGTACTTGACCGTTTTTATATTACTTT3180
TGTAAATATTCTTGTCCACATTCTACTTCAGCTTTGGATGTGGTTACCGAGTATCTGTAA3240
CCCTTGAATTTCTAGACAGTATTGCCACCTCTGGCCAAATATGCACTTTCCCTAGAAAGC3300
CATATTCCAGCAGTGAAACTTGTGCTATAGTGTATACCACCTGTACATACATTGTATAGG3360
CCATCTGTAAATATCCCAGAGAACAATCACTATTCTTAAGCACTTTGAAAATATTTCTAT3420
GTAAATTATTGTAAACTTTTTCAATGGTTGGGACAATGGCAATAGGACAAAACGGGTTAC3480
TAAGATGAAATTGCCAAAAAAATTTATAAACTAATTTTGGTACGTATGAATGATATCTTT3540
GACCTCAATGGAGGTTTGCAAAGACTGAGTGTTCAAACTACTGTACATTTTTTTTCAAGT3600
GCTAAAAAATTAAACCAAGCAGCTTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA3656
(2) INFORMATION FOR SEQ ID NO:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 873 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
MetGlyThrSerAlaLeuTrpAlaValTrpLeuLeuLeuAlaLeuCys
151015
TrpAlaProArgGluSerGlyAlaThrGlyThrGlyArgLysAlaLys
202530
CysGluProSerGlnPheGlnCysThrAsnGlyArgCysIleThrLeu
354045
LeuTrpLysCysAspGlyAspGluAspCysValAspGlySerAspGlu
505560
LysAsnCysValLysLysThrCysAlaGluSerAspPheValCysAsn
65707580
AsnGlyGlnCysValProSerArgTrpLysCysAspGlyAspProAsp
859095
CysGluAspGlySerAspGluSerProGluGlnCysHisMetArgThr
100105110
CysArgIleHisGluIleSerCysGlyAlaHisSerThrGlnCysIle
115120125
ProValSerTrpArgCysAspGlyGluAsnAspCysAspSerGlyGlu
130135140
AspGluGluAsnCysGlyAsnIleThrCysSerProAspGluPheThr
145150155160
CysSerSerGlyArgCysIleSerArgAsnPheValCysAsnGlyGln
165170175
AspAspCysSerAspGlySerAspGluLeuAspCysAlaProProThr
180185190
CysGlyAlaHisGluPheGlnCysSerThrSerSerCysIleProIle
195200205
SerTrpValCysAspAspAspAlaAspCysSerAspGlnSerAspGlu
210215220
SerLeuGluGlnCysGlyArgGlnProValIleHisThrLysCysPro
225230235240
AlaSerGluIleGlnCysGlySerGlyGluCysIleHisLysLysTrp
245250255
ArgCysAspGlyAspProAspCysLysAspGlySerAspGluValAsn
260265270
CysProSerArgThrCysArgProAspGlnPheGluCysGluAspGly
275280285
SerCysIleHisGlySerArgGlnCysAsnGlyIleArgAspCysVal
290295300
AspGlySerAspGluValAsnCysLysAsnValAsnGlnCysLeuGly
305310315320
ProGlyLysPheLysCysArgSerGlyGluCysIleAspIleSerLys
325330335
ValCysAsnGlnGluGlnAspCysArgAspTrpSerAspGluProLeu
340345350
LysGluCysHisIleAsnGluCysLeuValAsnAsnGlyGlyCysSer
355360365
HisIleCysLysAspLeuValIleGlyTyrGluCysAspCysAlaAla
370375380
GlyPheGluLeuIleAspArgLysThrCysGlyAspIleAspGluCys
385390395400
GlnAsnProGlyIleCysSerGlnIleCysIleAsnLeuLysGlyGly
405410415
TyrLysCysGluCysSerArgAlaTyrGlnMetAspLeuAlaThrGly
420425430
ValCysLysAlaValGlyLysGluProSerLeuIlePheThrAsnArg
435440445
ArgAspIleArgLysIleGlyLeuGluArgLysGluTyrIleGlnLeu
450455460
ValGluGlnLeuArgAsnThrValAlaLeuAspAlaAspIleAlaAla
465470475480
GlnLysLeuPheTrpAlaAspLeuSerGlnLysAlaIlePheSerAla
485490495
SerIleAspAspLysValGlyArgHisValLysMetIleAspAsnVal
500505510
TyrAsnProAlaAlaIleAlaValAspTrpValTyrLysThrIleTyr
515520525
TrpThrAspAlaAlaSerLysThrIleSerValAlaThrLeuAspGly
530535540
ThrLysArgLysPheLeuPheAsnSerAspLeuArgGluProAlaSer
545550555560
IleAlaValAspProLeuSerGlyPheValTyrTrpSerAspTrpGly
565570575
GluProAlaLysIleGluLysAlaGlyMetAsnGlyPheAspArgArg
580585590
ProLeuValThrAlaAspIleGlnTrpProAsnGlyIleThrLeuAsp
595600605
LeuIleLysSerArgLeuTyrTrpLeuAspSerLysLeuHisMetLeu
610615620
SerSerValAspLeuAsnGlyGlnAspArgArgIleValLeuLysSer
625630635640
LeuGluPheLeuAlaHisProLeuAlaLeuThrIlePheGluAspArg
645650655
ValTyrTrpIleAspGlyGluAsnGluAlaValTyrGlyAlaAsnLys
660665670
PheThrGlySerGluHisAlaThrLeuValAsnAsnLeuAsnAspAla
675680685
GlnAspIleIleValTyrHisGluLeuValGlnProSerGlyLysAsn
690695700
TrpCysGluGluAspMetGluAsnGlyGlyCysGluTyrLeuCysLeu
705710715720
ProAlaProGlnIleAsnAspHisSerProLysTyrThrCysSerCys
725730735
ProSerGlyTyrAsnValGluGluAsnGlyArgAspCysGlnSerThr
740745750
AlaThrThrValThrTyrSerGluThrLysAspThrAsnThrThrGlu
755760765
IleSerAlaThrSerGlyLeuValProGlyGlyIleAsnValThrThr
770775780
AlaValSerGluValSerValProProLysGlyThrSerAlaAlaTrp
785790795800
AlaIleLeuProLeuLeuLeuLeuValMetAlaAlaValGlyGlyTyr
805810815
LeuMetTrpArgAsnTrpGlnHisLysAsnMetLysSerMetAsnPhe
820825830
AspAsnProValTyrLeuLysThrThrGluGluAspLeuSerIleAsp
835840845
IleGlyArgHisSerAlaSerValGlyHisThrTyrProAlaIleSer
850855860
ValValSerThrAspAspAspLeuAla
865870
(2) INFORMATION FOR SEQ ID NO:3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9592 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: unknown
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:
GAATTCGCTAGCATCATCAATAATATACCTTATTTTGGATTGAAGCCAATATGATAATGA60
GGGGGTGGAGTTTGTGACGTGGCGCGGGGCGTGGGAACGGGGCGGGTGACGTAGTAGTGT120
GGCGGAAGTGTGATGTTGCAAGTGTGGCGGAACACATGTAAGCGACGGATGTGGCAAAAG180
TGACGTTTTTGGTGTGCGCCGGTGTACACAGGAAGTGACAATTTTCGCGCGGTTTTAGGC240
GGATGTTGTAGTAAATTTGGGCGTAACCGAGTAAGATTTGGCCATTTTCGCGGGAAAACT300
GAATAAGAGGAAGTGAAATCTGAATAATTTTGTGTTACTCATAGCGCGTAATATTTGTCT360
AGGGAGATCAGCCTGCAGGTCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCG420
CCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATA480
GGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTA540
CATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCC600
GCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTAC660
GTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGA720
TAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTG780
TTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACG840
CAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCTCTGGCTAACT900
AGAGAACCCACTGCTTAACTGGCTTATCGAAATTAATACGACTCACTATAGGGAGACCCA960
AGCTTCTCTGCGGGCCGCGGGTGCGGGTCGTCGCTACCGGCTCTCTCCGTTCTGTGCTCT1020
CTTCTGCTCTCGGCTCCCCACCCCCTCTCCCTTCCCTCCTCTCCCCTTGCCTCCCCTCCT1080
CTGCAGCGCCTGCATTATTTTCTGCCCGCAGCTCGGCTTGCACTGCTGCTGCAGCCCGGG1140
GAGGTGGCTGGGTGGGTGGGGAGGAGACTGTGCAAGTTGTAGGGGAGGGGGTGCCCTCTT1200
CTTCCCCGCTCCCTTCCCCAGCCAAGTGGTTCCCCTCCTTCTCCCCCTTTCCCCTCCCAG1260
CCCCCACCTTCTTCCTCTTTCGGAAGGGCTGGTAACTTGTCGTGCGGAGCGAACGGCGGC1320
GGCGGCGGCGGCGGCGGCACCATCCAGGCGGGCACCATGGGCACGTCCGCGCTCTGGGCC1380
GTCTGGCTGCTGCTCGCGCTGTGCTGGGCGCCCCGGGAGAGCGGCGCCACCGGAACCGGG1440
AGAAAAGCCAAATGTGAACCCTCCCAATTCCAGTGCACAAATGGTCGCTGTATTACGCTG1500
TTGTGGAAATGTGATGGGGATGAAGACTGTGTTGACGGCAGTGATGAAAAGAACTGTGTA1560
AAGAAGACGTGTGCTGAATCTGACTTCGTGTGCAACAATGGCCAGTGTGTTCCCAGCCGA1620
TGGAAGTGTGATGGAGATCCTGACTGCGAAGATGGTTCAGATGAAAGCCCAGAACAGTGC1680
CATATGAGAACATGCCGCATACATGAAATCAGCTGTGGCGCCCATTCTACTCAGTGTATC1740
CCAGTGTCCTGGAGATGTGATGGTGAAAATGATTGTGACAGTGGAGAAGATGAAGAAAAC1800
TGTGGCAATATAACATGTAGTCCCGACGAGTTCACCTGCTCCAGTGGCCGCTGCATCTCC1860
AGGAACTTTGTATGCAATGGCCAGGATGACTGCAGCGATGGCAGTGATGAGCTGGACTGT1920
GCCCCGCCAACCTGTGGCGCCCATGAGTTCCAGTGCAGCACCTCCTCCTGCATCCCCATC1980
AGCTGGGTATGCGACGATGATGCAGACTGCTCCGACCAATCTGATGAGTCCCTGGAGCAG2040
TGTGGCCGTCAGCCAGTCATACACACCAAGTGTCCAGCCAGCGAAATCCAGTGCGGCTCT2100
GGCGAGTGCATCCATAAGAAGTGGCGATGTGATGGGGACCCTGACTGCAAGGATGGCAGT2160
GATGAGGTCAACTGTCCCTCTCGAACTTGCCGACCTGACCAATTTGAATGTGAGGATGGC2220
AGCTGCATCCATGGCAGCAGGCAGTGTAATGGTATCCGAGACTGTGTCGATGGTTCCGAT2280
GAAGTCAACTGCAAAAATGTCAATCAGTGCTTGGGCCCTGGAAAATTCAAGTGCAGAAGT2340
GGAGAATGCATAGATATCAGCAAAGTATGTAACCAGGAGCAGGACTGCAGGGACTGGAGT2400
GATGAGCCCCTGAAAGAGTGTCATATAAACGAATGCTTGGTAAATAATGGTGGATGTTCT2460
CATATCTGCAAAGACCTAGTTATAGGCTACGAGTGTGACTGTGCAGCTGGGTTTGAACTG2520
ATAGATAGGAAAACCTGTGGAGATATTGATGAATGCCAAAATCCAGGAATCTGCAGTCAA2580
ATTTGTATCAACTTAAAAGGCGGTTACAAGTGTGAATGTAGTCGTGCCTATCAAATGGAT2640
CTTGCTACTGGCGTGTGCAAGGCAGTAGGCAAAGAGCCAAGTCTGATCTTCACTAATCGA2700
AGAGACATCAGGAAGATTGGCTTAGAGAGGAAAGAATATATCCAACTAGTTGAACAGCTA2760
AGAAACACTGTGGCTCTCGATGCTGACATTGCTGCCCAGAAACTATTCTGGGCCGATCTA2820
AGCCAAAAGGCTATCTTCAGTGCCTCAATTGATGACAAGGTTGGTAGACATGTTAAAATG2880
ATCGACAATGTCTATAATCCTGCAGCCATTGCTGTTGATTGGGTGTACAAGACCATCTAC2940
TGGACTGATGCGGCTTCTAAGACTATTTCAGTAGCTACCCTAGATGGAACCAAGAGGAAG3000
TTCCTGTTTAACTCTGACTTGCGAGAGCCTGCCTCCATAGCTGTGGACCCACTGTCTGGC3060
TTTGTTTACTGGTCAGACTGGGGTGAACCAGCTAAAATAGAAAAAGCAGGAATGAATGGA3120
TTCGATAGACGTCCACTGGTGACAGCGGATATCCAGTGGCCTAACGGAATTACACTTGAC3180
CTTATAAAAAGTCGCCTCTATTGGCTTGATTCTAAGTTGCACATGTTATCCAGCGTGGAC3240
TTGAATGGCCAAGATCGTAGGATAGTACTAAAGTCTCTGGAGTTCCTAGCTCATCCTCTT3300
GCACTAACAATATTTGAGGATCGTGTCTACTGGATAGATGGGGAAAATGAAGCAGTCTAT3360
GGTGCCAATAAATTCACTGGATCAGAGCATGCCACTCTAGTCAACAACCTGAATGATGCC3420
CAAGACATCATTGTCTATCATGAACTTGTACAGCCATCAGGTAAAAATTGGTGTGAAGAA3480
GACATGGAGAATGGAGGATGTGAATACCTATGCCTGCCAGCACCACAGATTAATGATCAC3540
TCTCCAAAATATACCTGTTCCTGTCCCAGTGGGTACAATGTAGAGGAAAATGGCCGAGAC3600
TGTCAAAGTACTGCAACTACTGTGACTTAGAGACAAAAGATACGAACACAACAGAAATTT3660
CAGCAACTAGTGGACTAGTTCCTGGAGGGATCAATGTGACCACAGCAGTATCAGAGGTCA3720
GTGTTCCCCCAAAAGGGACTTCTGCCGCATGGGCCATTCTTCCTCTCTTGCTCTTAGTGA3780
TGGCAGCAGTAGGTGGCTACTTGATGTGGCGGAATTGGCAACACAAGAACATGAAAAGCA3840
TGAACTTTGACAATCCTGTGTACTTGAAAACCACTGAAGAGGACCTCTCCATAGACATTG3900
GTAGACACAGTGCTTCTGTTGGACACACGTACCCAGCAATATCAGTTGTAAGCACAGATG3960
ATGATCTAGCTTGACTTCTGTGACAAATGTTGACCTTTGAGGTCTAAACAAATAATACCC4020
CCGTCGGAATGGTAACCGAGCCAGCAGCTGAAGTCTCTTTTTCTTCCTCTCGGCTGGAAG4080
AACATCAAGATACCTTTGCGTGGATCAAGCTTGGTACCGAGCTCGGATCCACTAGTAACG4140
GCCGCCAGTGTGCTGGAATTCTGCAGATATCCATCACACTGGCGGCCGCGGGGATCCAGA4200
CATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATG4260
CTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAA4320
ACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGA4380
GGTTTTTTCGGATCCTCTAGAGTCGACCTGCAGGCTGATCTGGAAGGTGCTGAGGTACGA4440
TGAGACCCGCACCAGGTGCAGACCCTGCGAGTGTGGCGGTAAACATATTAGGAACCAGCC4500
TGTGATGCTGGATGTGACCGAGGAGCTGAGGCCCGATCACTTGGTGCTGGCCTGCACCCG4560
CGCTGAGTTTGGCTCTAGCGATGAAGATACAGATTGAGGTACTGAAATGTGTGGGCGTGG4620
CTTAAGGGTGGGAAAGAATATATAAGGTGGGGGTCTTATGTAGTTTTGTATCTGTTTTGC4680
AGCAGCCGCCGCCGCCATGAGCACCAACTCGTTTGATGGAAGCATTGTGAGCTCATATTT4740
GACAACGCGCATGCCCCCATGGGCCGGGGTGCGTCAGAATGTGATGGGCTCCAGCATTGA4800
TGGTCGCCCCGTCCTGCCCGCAAACTCTACTACCTTGACCTACGAGACCGTGTCTGGAAC4860
GCCGTTGGAGACTGCAGCCTCCGCCGCCGCTTCAGCCGCTGCAGCCACCGCCCGCGGGAT4920
TGTGACTGACTTTGCTTTCCTGAGCCCGCTTGCAAGCAGTGCAGCTTCCCGTTCATCCGC4980
CCGCGATGACAAGTTGACGGCTCTTTTGGCACAATTGGATTCTTTGACCCGGGAACTTAA5040
TGTCGTTTCTCAGCAGCTGTTGGATCTGCGCCAGCAGGTTTCTGCCCTGAAGGCTTCCTC5100
CCCTCCCAATGCGGTTTAAAACATAAATAAAAAACCAGACTCTGTTTGGATTTGGATCAA5160
GCAAGTGTCTTGCTGTCTTTATTTAGGGGTTTTGCGCGCGCGGTAGGCCCGGGACCAGCG5220
GTCTCGGTCGTTGAGGGTCCTGTGTATTTTTTCCAGGACGTGGTAAAGGTGACTCTGGAT5280
GTTCAGATACATGGGCATAAGCCCGTCTCTGGGGTGGAGGTAGCACCACTGCAGAGCTTC5340
ATGCTGCGGGGTGGTGTTGTAGATGATCCAGTCGTAGCAGGAGCGCTGGGCGTGGTGCCT5400
AAAAATGTCTTTCAGTAGCAAGCTGATTGCCAGGGGCAGGCCCTTGGTGTAAGTGTTTAC5460
AAAGCGGTTAAGCTGGGATGGGTGCATACGTGGGGATATGAGATGCATCTTGGACTGTAT5520
TTTTAGGTTGGCTATGTTCCCAGCCATATCCCTCCGGGGATTCATGTTGTGCAGAACCAC5580
CAGCACAGTGTATCCGGTGCACTTGGGAAATTTGTCATGTAGCTTAGAAGGAAATGCGTG5640
GAAGAACTTGGAGACGCCCTTGTGACCTCCAAGATTTTCCATGCATTCGTCCATAATGAT5700
GGCAATGGGCCCACGGGCGGCGGCCTGGGCGAAGATATTTCTGGGATCACTAACGTCATA5760
GTTGTGTTCCAGGATGAGATCGTCATAGGCCATTTTTACAAAGCGCGGGCGGAGGGTGCC5820
AGACTGCGGTATAATGGTTCCATCCGGCCCAGGGGCGTAGTTACCCTCACAGATTTGCAT5880
TTCCCACGCTTTGAGTTCAGATGGGGGGATCATGTCTACCTGCGGGGCGATGAAGAAAAC5940
GGTTTCCGGGGTAGGGGAGATCAGCTGGGAAGAAAGCAGGTTCCTGAGCAGCTGCGACTT6000
ACCGCAGCCGGTGGGCCCGTAAATCACACCTATTACCGGGTGCAACTGGTAGTTAAGAGA6060
GCTGCAGCTGCCGTCATCCCTGAGCAGGGGGGCCACTTCGTTAAGCATGTCCCTGACTCG6120
CATGTTTTCCCTGACCAAATCCGCCAGAAGGCGCTCGCCGCCCAGCGATAGCAGTTCTTG6180
CAAGGAAGCAAAGTTTTTCAACGGTTTGAGACCGTCCGCCGTAGGCATGCTTTTGAGCGT6240
TTGACCAAGCAGTTCCAGGCGGTCCCACAGCTCGGTCACCTGCTCTACGGCATCTCGATC6300
CAGCATATCTCCTCGTTTCGCGGGTTGGGGCGGCTTTCGCTGTACGGCAGTAGTCGGTGC6360
TCGTCCAGACGGGCCAGGGTCATGTCTTTCCACGGGCGCAGGGTCCTCGTCAGCGTAGTC6420
TGGGTCACGGTGAAGGGGTGCGCTCCGGGCTGCGCGCTGGCCAGGGTGCGCTTGAGGCTG6480
GTCCTGCTGGTGCTGAAGCGCTGCCGGTCTTCGCCCTGCGCGTCGGCCAGGTAGCATTTG6540
ACCATGGTGTCATAGTCCAGCCCCTCCGCGGCGTGGCCCTTGGCGCGCAGCTTGCCCTTG6600
GAGGAGGCGCCGCACGAGGGGCAGTGCAGACTTTTGAGGGCGTAGAGCTTGGGCGCGAGA6660
AATACCGATTCCGGGGAGTAGGCATCCGCGCCGCAGGCCCCGCAGACGGTCTCGCATTCC6720
ACGAGCCAGGTGAGCTCTGGCCGTTCGGGGTCAAAAACCAGGTTTCCCCCATGCTTTTTG6780
ATGCGTTTCTTACCTCTGGTTTCCATGAGCCGGTGTCCACGCTCGGTGACGAAAAGGCTG6840
TCCGTGTCCCCGTATACAGACTTGAGAGGCCTGTCCTCGACCGATGCCCTTGAGAGCCTT6900
CAACCCAGTCAGCTCCTTCCGGTGGGCGCGGGGCATGACTATCGTCGCCGCACTTATGAC6960
TGTCTTCTTTATCATGCAACTCGTAGGACAGGTGCCGGCAGCGCTCTGGGTCATTTTCGG7020
CGAGGACCGCTTTCGCTGGAGCGCGACGATGATCGGCCTGTCGCTTGCGGTATTCGGAAT7080
CTTGCACGCCCTCGCTCAAGCCTTCGTCACTGGTCCCGCCACCAAACGTTTCGGCGAGAA7140
GCAGGCCATTATCGCCGGCATGGCGGCCGACGCGCTGGGCTACGTCTTGCTGGCGTTCGC7200
GACGCGAGGCTGGATGGCCTTCCCCATTATGATTCTTCTCGCTTCCGGCGGCATCGGGAT7260
GCCCGCGTTGCAGGCCATGCTGTCCAGGCAGGTAGATGACGACCATCAGGGACAGCTTCA7320
AGGATCGCTCGCGGCTCTTACCAGCCTAACTTCGATCACTGGACCGCTGATCGTCACGGC7380
GATTTATGCCGCCTCGGCGAGCACATGGAACGGGTTGGCATGGATTGTAGGCGCCGCCCT7440
ATACCTTGTCTGCCTCCCCGCGTTGCGTCGCGGTGCATGGAGCCGGGCCACCTCGACCTG7500
AATGGAAGCCGGCGGCACCTCGCTAACGGATTCACCACTCCAAGAATTGGAGCCAATCAA7560
TTCTTGCGGAGAACTGTGAATGCGCAAACCAACCCTTGGCAGAACATATCCATCGCGTCC7620
GCCATCTCCAGCAGCCGCACGCGGCGCATCTCGGGCAGCGTTGGGTCCTGGCCACGGGTG7680
CGCATGATCGTGCTCCTGTCGTTGAGGACCCGGCTAGGCTGGCGGGGTTGCCTTACTGGT7740
TAGCAGAATGAATCACCGATACGCGAGCGAACGTGAAGCGACTGCTGCTGCAAAACGTCT7800
GCGACCTGAGCAACAACATGAATGGTCTTCGGTTTCCGTGTTTCGTAAAGTCTGGAAACG7860
CGGAAGTCAGCGCCCTGCACCATTATGTTCCGGATCTGCATCGCAGGATGCTGCTGGCTA7920
CCCTGTGGAACACCTACATCTGTATTAACGAAGCCTTTCTCAATGCTCACGCTGTAGGTA7980
TCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCA8040
GCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGA8100
CTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGG8160
TGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGG8220
TATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGG8280
CAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAG8340
AAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAA8400
CGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGAT8460
CCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTC8520
TGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTC8580
ATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATC8640
TGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGC8700
AATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTC8760
CATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTT8820
GCGCAACGTTGTTGCCATTGCTGCAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGC8880
TTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAA8940
AAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTT9000
ATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATG9060
CTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACC9120
GAGTTGCTCTTGCCCGGCGTCAACACGGGATAATACCGCGCCACATAGCAGAACTTTAAA9180
AGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTT9240
GAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTT9300
CACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAG9360
GGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTA9420
TCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAAT9480
AGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGACGTCTAAGAAACCATTATTAT9540
CATGACATTAACCTATAAAAATAGGCGTATCACGAGGCCCTTTCGTCTTCAA9592
(2) INFORMATION FOR SEQ ID NO:4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: unknown
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:
TAGTAAATTTGGGC14
(2) INFORMATION FOR SEQ ID NO:5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: unknown
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:
AGTAAGATTTGGCC14
(2) INFORMATION FOR SEQ ID NO:6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: unknown
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:
AGTGAAATCTGAAT14
(2) INFORMATION FOR SEQ ID NO:7:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: unknown
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:
GAATAATTTTGTGT14
(2) INFORMATION FOR SEQ ID NO:8:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: unknown
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:
CGTAATATTTGTCT14
__________________________________________________________________________

Claims

What is claimed is:

1. A recombinant adenoviral vector comprising a human VLDL receptor gene operatively linked to regulatory sequences directing expression of said receptor gene in a hepatocyte.

2. The vector according to claim 1 further comprising adenovirus 5' and 3' cis-elements necessary for replication and virion encapsidation.

3. The vector according to claim 1 further comprising a deletion in all or a portion of the E1 gene.

4. The vector according to claim 1 further comprising a deletion in all or a portion of the E3 gene.

5. A method for delivering a VLDL receptor gene into a hepatocyte comprising introducing into said hepatocyte an effective amount of a recombinant adenoviral vector comprising a human VLDL receptor gene operatively linked to regulatory sequences directing expression of the VLDL receptor in said hepatocyte.

6. A mammalian hepatocyte, which expresses a human VLDL receptor introduced therein through transduction of said hepatocyte by an adenoviral vector comprising a human VLDL receptor gene operatively linked to regulatory sequences directing expression of said receptor gene in said hepatocyte.

7. A method for treating a patient having a disorder characterized by an elevated concentration of LDL in plasma comprising administering into the bloodstream of said patient an effective amount of a recombinant adenoviral vector comprising: a human VLDL receptor gene operatively linked to regulatory sequences directing expression of the VLDL receptor in hepatocytes.

8. The method according to claim 7 wherein said disorder is familial hypercholesterolemia or familial combined hyperlipidemia.

9. A method for decreasing the levels of VLDL and LDL in the plasma of a patient, comprising administering into the bloodstream of said patient an effective amount of an adenoviral vector comprising a human VLDL receptor gene operatively linked to regulatory sequences directing expression of the VLDL receptor in hepatocytes.

10. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an adenoviral vector, said vector comprising a human VLDL receptor gene operatively linked to regulatory sequences directing expression of said receptor gene in a hepatocyte.

11. The composition according to claim 10 wherein said adenoviral vector comprises adenovirus 5' and 3' cis-elements necessary for replication and virion encapsidation.

12. The composition according to claim 10 wherein said adenoviral vector comprises a deletion in all or a portion of the E1 gene.

13. The composition according to claim 10 wherein said adenoviral vector comprises a deletion in all or a portion of the E3 gene.